<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>cg - Category - MilkyÊùøÊùø„ÅÆÂçöÂÆ¢</title>
        <link>https://uioqps.github.io/categories/cg/</link>
        <description>cg - Category - MilkyÊùøÊùø„ÅÆÂçöÂÆ¢</description>
        <generator>Hugo -- gohugo.io</generator><language>en</language><copyright>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</copyright><lastBuildDate>Sun, 23 Feb 2020 21:16:02 &#43;0000</lastBuildDate><atom:link href="https://uioqps.github.io/categories/cg/" rel="self" type="application/rss+xml" /><item>
    <title>„Äêbioinfo„Äë-Q&amp;A-75</title>
    <link>https://uioqps.github.io/bioinfo-q-a-75/</link>
    <pubDate>Sun, 23 Feb 2020 21:16:02 &#43;0000</pubDate>
    <author>Milky</author>
    <guid>https://uioqps.github.io/bioinfo-q-a-75/</guid>
    <description><![CDATA[single cell Â¶Ç‰ΩïÁ†îÁ©∂ÂÆø‰∏ªÁªÜËÉûÂíåÁóÖÂéü‰Ωì‰πãÈó¥ÁöÑÂÖ≥Á≥ª  Single-Cell RNA Sequencing to Understand Host‚àíPathogen Interactions
 Á†îÁ©∂ÁóÖÂéü‰Ωì‰∏∫‰ªÄ‰πàË¶ÅÁî®ÂçïÁªÜËÉûÊµãÂ∫èÔºü ‰∏∫‰ªÄ‰πàË¶ÅÂÅöÂçïÁªÜËÉûÊµãÂ∫èÔºåÂÖ∂ÂÆûÂ∑≤ÁªèÊòØ‰∏çË®ÄËÄåÂñªÁöÑ‰∫ÜÔºå‰ªé‰∏ãÈù¢‰∏ÄÂπÖÂõæ‰πüËÉΩ‰ΩìÁé∞Âá∫Êù•„ÄÇÁ±ª‰ººËÇøÁò§ÁöÑÂºÇË¥®ÊÄßÔºåÂæÆÁîüÁâ©ÔºåÂ¶ÇÁªÜËèå‰πüÂ≠òÂú®ÂæàÂº∫ÁöÑËèåÁæ§ÂºÇË¥®ÊÄßÔºåÈô§‰∫ÜÁªÜËèåÁöÑ‰∫öÂÖãÈöÜ‰πãÂ§ñÔºåËøòÊúâÂêàÂπ∂ÊÑüÊüìÁ≠âÂ§çÊùÇÁöÑÁé∞Ë±°„ÄÇÂ¶ÇÂõæÊâÄÁ§∫ÁöÑ‰∏âÁßçÁªÜËÉûÁæ§‰ΩìÁâπÂæÅÔºåÂèØËÉΩÂú®bulkÊµãÂ∫èÂêéÂæóÂà∞Áõ∏ÂêåÁöÑË°®ÂûãÔºåÂõ†Ê≠§ËÄåÊé©Áõñ‰∫ÜÁúüÂÆûÁöÑÁé∞Ë±°„ÄÇ‰∏Ä‰∏™ÂÖ∏ÂûãÁöÑ‰æãÂ≠êÂá∫Áé∞Âú®Â§ßËÇ†ÊùÜËèåE.coliÂèåÁ®≥ÊÄÅÔºàbistabilityÔºâÁöÑÁ†îÁ©∂‰∏≠„ÄÇÂèåÁ®≥ÊÄÅÊèèËø∞‰∫Ü‰∏ÄÁßçÂèØÈÄÜÁöÑÂèåÂ≥∞Âü∫Âõ†Ë°®ËææÔºåÂØºËá¥‰∏§‰∏™‰∏çÂêåÁöÑÂÖ±Â≠ò‰∫öÁæ§„ÄÇÈù¢ÂØπÊäóÁîüÁ¥†Êö¥Èú≤Ôºå‰∏ÄÂ∞èÈÉ®ÂàÜÁªÜËèåÁæ§‰Ωì‰ºöËΩ¨ÂåñÊàêÊåÅ‰πÖÁªÜËÉûÔºàpersister cellsÔºâÔºå‰ªçÁÑ∂‰ª•ÊûÅ‰ΩéÁöÑÁîüÈïøÈÄüÂ∫¶Â≠òÊ¥ª„ÄÇ
Èô§‰∫ÜÁªÜËèåÁöÑËèåÁæ§ÂºÇË¥®ÊÄßÂíåÂ∑≤Áü•ÁöÑÂÆø‰∏ªÔºàÂÖçÁñ´ÔºâÁªÜËÉûÁöÑÂºÇË¥®ÊÄßÔºåÁªÜËèåÂú®ÂÆø‰∏ªÁªÜËÉû‰∏≠ÁöÑÂØÑÁîüÁä∂ÊÄÅÁöÑÂ§öÊ†∑ÊÄßÂíåÂä®ÊÄÅÂèòÂåñÂèà‰ΩøÂæóËøôÁ±ªÁ†îÁ©∂ÁöÑÂ§çÊùÇÁ®ãÂ∫¶Êõ¥‰∏ä‰∏ÄÂ±ÇÊ•º„ÄÇÂΩìÁªÜËèåÊé•Ëß¶Âà∞ÂÆø‰∏ªÁªÜËÉûÊó∂ÔºåÁªÜËèåÂèØËÉΩÂÜÖÂåñÔºå‰πüÂèØËÉΩ‰∏çÂèëÁîüÂÜÖÂåñ„ÄÇÂΩìÁªÜËèåÂÜÖÂåñÂèëÁîü‰∫ÜÔºåÂÆø‰∏ªÁªÜËÉû‰ΩúÂá∫ÁöÑÂ∫îÁ≠îÊúâÂèØËÉΩÊòØÁîüÂ≠òÔºåÊ∏ÖÈô§ÊàñËÄÖÊ≠ª‰∫°„ÄÇÁîüÂ≠òÁä∂ÊÄÅ‰∏ãÔºåÁªÜËèåÂú®ÂÆø‰∏ªÁªÜËÉûÂÜÖÁöÑÂèØËÉΩÂèëÁîüÂ¢ûÊÆñÔºå‰πüÂèØËÉΩË¢´ÊäëÂà∂„ÄÇÊ≠ª‰∫°Áä∂ÊÄÅ‰∏ãÔºåÁªÜËèåÂèØËÉΩÂÖ±‰∫°‰πüÂèØËÉΩÈÄÉÈÄ∏„ÄÇ‰∏çÂêåÁöÑÊÑüÊüìÁªìÂ±ÄÂèØËÉΩÁî±‰∫éÁªÜËèåÁöÑË°®ËææË∞±Â∑ÆÂºÇÊàñËÄÖÂÆø‰∏ªÁªÜËÉûÁöÑË°®ËææË∞±Â∑ÆÂºÇÂØºËá¥„ÄÇËÄåÁõ∏ÂêåÁöÑÊÑüÊüìÁªìÂ±Ä‰πüÊúâÂèØËÉΩÊòØÊù•Ê∫ê‰∫éÂÖ∑ÊúâË°®ËææÂ∑ÆÂºÇÁöÑ‰∏çÂêåÁóÖÂéü‰Ωì-ÂÆø‰∏ªÁªÑÂêà„ÄÇÂê¨ÂÆåÊòØ‰∏çÊòØËßâÂæóÁâπÂà´ÊÉ≥ÂêêË°Äü§ÆÔºüÂçïÁªÜËÉûÊµãÂ∫èÂ∞±ÂÉè‰∏Ä‰∏™ÊîæÂ§ßÈïú‰∏ÄÊ†∑ÔºåÂèØ‰ª•ËÆ©Êàë‰ª¨Êõ¥ÁªÜËá¥ÁöÑËßÇÂØüÁóÖÂéü‰ΩìÊÑüÊüìÁöÑËøáÁ®ã„ÄÇÂõ†Ê≠§Êàë‰ª¨ÈùûÂ∏∏ÈúÄË¶ÅÂÆÉ„ÄÇ
Ë∂äÊù•Ë∂äÂ§öÁöÑÂçïÁªÜËÉûÊµãÂ∫èÊñπÊ≥ïÊ∂åÁé∞Âá∫Êù•ÔºåÂØπÊµãÂ∫èËøáÁ®ã‰∏≠‰ªª‰ΩïÁéØËäÇÁöÑÂÅèÂÄöÊúâ‰∫ÜË∂äÊù•Ë∂äÂ•ΩÁöÑ‰øÆÊ≠£ÊñπÊ°à„ÄÇÊ≠§Â§ñËøòÊúâÂïÜ‰∏öÂåñÁöÑÊµãÂ∫èÂπ≥Âè∞ÔºåÂ¶ÇFluidigm&rsquo;s C1Á≥ªÁªüÂíå10x GenomicsÔºå‰ΩøÂçïÁªÜËÉûÊµãÂ∫è‰ªéÁªÜËÉûÂàÜÈÄâ„ÄÅË£ÇËß£„ÄÅRNAÊèêÂèñ„ÄÅcDNAÂêàÊàêÂà∞Âª∫Â∫ìÊµãÂ∫èÂèòÊàêÊµÅÊ∞¥Á∫ø‰Ωú‰∏ö„ÄÇÈíàÂØπÂçïÁªÜËÉûÁöÑÊàêÂ•óÊï∞ÊçÆÂàÜÊûêÊñπÊ≥ï‰πü‰∏çÊñ≠Ë¢´ÂºÄÂèëÂá∫Êù•ÔºåÂ¶ÇSeuratÂíåSCDEÂ∑≤Êï¥Âêà‰∫ÜÂçïÁªÜËÉûÊµãÂ∫èÊï∞ÊçÆÂàÜÊûêÁöÑÂ§öÊ≠•ÂàÜÊûêÊµÅÁ®ã„ÄÇ
Â∞±ÂÉèÊòØÂΩìÂπ¥‰∫∫Á±ªÂü∫Âõ†ÁªÑËÆ°ÂàíÁöÑÂçáÁ∫ßÁâàÔºåÂ§öÈ°πÂçïÁªÜËÉûÂ±ÇÈù¢ÁöÑÁ†îÁ©∂ËÆ°ÂàíÁõÆÂâçÊ≠£Âú®ËøõË°å‰∏≠ÔºåÂ¶ÇChan ZuckerbergÁ†îÁ©∂ÊâÄÊîØÊåÅÁöÑThe Human Cell AtlasÔºåNIHÊîØÊåÅÁöÑHuman BioMolecular Atlas Program„ÄÇËøô‰∫õËÆ°Âàí‰∏≠ÁßëÂ≠¶ÂÆ∂‰ª¨Â∞ÜÂØπÊâÄÊúâ‰∫∫‰ΩìÁªÜËÉûÁ±ªÂûãÂíåÁªÑÁªáÁ±ªÂûãËøõË°åDNA„ÄÅRNAÂíåËõãÁôΩÊ∞¥Âπ≥ÁöÑÁ†îÁ©∂Ôºå‰ªéËÄåÂú®ÁªÜËÉûÊ∞¥Âπ≥Á†îÁ©∂Â§çÊùÇÊú∫‰ΩìÁöÑÁîüÁâ©Â••Áßò„ÄÇÈô§Ê≠§‰πãÂ§ñÔºåÈíàÂØπÊÑüÊüìÂíåÂÖçÁñ´È¢ÜÂüüÔºåImmunological Genome ProjectÈ°πÁõÆËÆ°ÂàíÈíàÂØπÂ∞èÈº†Ê®°ÂûãÔºåÊ£ÄÊµãÊâÄÊúâÂÖçÁñ´ÁªÜËÉû‰∫öÂûãÁöÑË°®ËææË∞±Êï∞ÊçÆÔºåÂª∫Á´ãÊï∞ÊçÆÂ∫ìÔºå‰∏∫Á†îÁ©∂ÂÖçÁñ´ÁªÜËÉûË°å‰∏∫ÔºåËøõÂåñÂíåÂèëÁé∞Êñ∞ÁöÑÂÖçÁñ´ÁªÜËÉû‰∫öÂûãÊèê‰æõÊîØÊåÅ„ÄÇËØ•Êï∞ÊçÆÂ∫ìÊî∂ÂΩï‰∫ÜÂ∞èÈº†Ê®°ÂûãÂú®‰∏çÂêåÊÑüÊüìÁñæÁóÖÁä∂ÊÄÅ‰∏ãÔºåÂÖçÁñ´ÁªÜËÉûÁöÑÂçïÁªÜËÉûÊµãÂ∫èÊï∞ÊçÆ„ÄÇ
ÂæÆÁîüÁâ©ÁóÖÂéü‰Ωì‰∏éÂÆø‰∏ªÂÖ≥Á≥ªÁöÑÁ†îÁ©∂ËøõÂ±ïÔºà‰∏æ‰æãÔºâ ÊúÄÊó©ÁöÑ‰∏§ÁØá‰ªéÂçïÁªÜËÉûÂ±ÇÈù¢Á†îÁ©∂ÂÆø‰∏ª-ÁªÜËèåÁõ∏‰∫íÂÖ≥Á≥ªÁöÑÊñáÁ´†Á†îÁ©∂‰∫ÜÈº†‰º§ÂØíÊ≤ôÈó®Ê∞èËèåÂíåÂÆø‰∏ªÂ∑®Âô¨ÁªÜËÉûÁöÑÁõ∏‰∫í‰ΩúÁî®„ÄÇÁ†îÁ©∂‰∏≠‰ªÖÂØπÂÆø‰∏ªÁªÜËÉûËøõË°å‰∫ÜÂçïÁªÜËÉûÊµãÂ∫èÔºåËÄåÁóÖÂéüËèåÂàôÊòØÂà©Áî®ËçßÂÖâÊ†áËÆ∞ËøõË°åÊ£ÄÊµã„ÄÇAvrahamÁ≠â‰∫∫Á†îÁ©∂ÂèëÁé∞ÁªÜËèåÁöÑÂèòÂºÇÊÄßÂÜ≥ÂÆö‰∫ÜÂÆø‰∏ªÁªÜËÉûÁöÑÂ∫îÁ≠îÂ∑ÆÂºÇ„ÄÇÊÑüÊüìÁöÑÂ∑®Âô¨ÁªÜËÉûÁöÑËΩ¨ÂΩïÁªÑÂàÜÊûêÊè≠Á§∫‰∫Ü‰∏ÄÁªÑÂèåÂ≥∞Ë°®ËææÂü∫Âõ†ÔºåÂÆÉ‰ª¨ÂØåÈõÜÂú®IÂûãÂπ≤Êâ∞Á¥†Â∫îÁ≠îÂèçÂ∫îÂäüËÉΩ‰∏ãÔºåÂπ∂‰∏î‰ªÖÂú®‰∏âÂàÜ‰πã‰∏ÄÁöÑÊÑüÊüìÁªÜËÉû‰∏≠Ë¢´ËØ±ÂØº„ÄÇËØ•Â∫îÁ≠îÂèçÂ∫îÁä∂ÊÄÅ‰∏éÁªÜËèåÁöÑPhoPQÂèåÁªÑÂàÜÁ≥ªÁªüÂØÜÂàáÁõ∏ÂÖ≥ÔºåÁî±ÁªÜËèåË°®Èù¢LPS‰ªãÂØº„ÄÇÁ†îÁ©∂Ëøõ‰∏ÄÊ≠•ÂèëÁé∞ÂÆø‰∏ªÁªÜËÉûÂ¶ÇÊûúÂÜÖÂåñ‰∫ÜÈ´òPhoPQÊ¥ªÊÄßÁöÑÁªÜËèåÔºåÂàôÂëàÈ´òIÂûãÂπ≤Êâ∞Á¥†Â∫îÁ≠îÂèçÂ∫îÔºõËÄåÂÆø‰∏ªÁªÜËÉûÂ¶ÇÊûúÂÜÖÂåñ‰∫Ü‰ΩéPhoPQÊ¥ªÊÄßÁöÑÁªÜËèåÔºåÂàôÂëà‰ΩéIÂûãÂπ≤Êâ∞Á¥†Â∫îÁ≠îÂèçÂ∫î„ÄÇÁ†îÁ©∂ËØÅÊòé‰∫ÜÂÆø‰∏ªÁöÑÁªÜËÉûÁöÑÂÖçÁñ´Â∫îÁ≠îÂèçÂ∫îÂ∑ÆÂºÇÊòØÊù•Ê∫ê‰∫éÊÑüÊüìÁªÜËèåÁöÑËèåÁæ§Â∑ÆÂºÇÔºåËÄåÈùûÂÆø‰∏ªÁªÜËÉûÁöÑÁöÑÂºÇË¥®ÊÄß„ÄÇSalibaÁ≠â‰∫∫ÂàôÈÄöËøábulk dual-RNAseqÂèëÁé∞ÂÜÖÂåñÁöÑÂ¢ûÊÆñÂûãÂíåÈùûÂ¢ûÊÆñÂûãÊ≤ôÈó®Ê∞èËèåÂèØ‰ª•ÂºïËµ∑ÂÆø‰∏ªÂ∑®Âô¨ÁªÜËÉû‰∏çÂêåÁöÑË°®ÂûãÔºåÊúâÂà©‰∫éËá™Â∑±ÁöÑÁîüÂ≠ò„ÄÇ
ÊñáÁ´†‰ΩúËÄÖËÆ§‰∏∫ÁõÆÂâçÁ†îÁ©∂ËøõÂ±ïÊâÄÊè≠Á§∫ÁöÑÈóÆÈ¢òËøòÊØîËæÉÂàùÁ∫ßÔºå‰ªñÊèêÂá∫‰∫ÜÊõ¥Â§öÁöÑÁ†îÁ©∂ËÆÆÈ¢òÊúâÂæÖÊàë‰ª¨ÂéªÊåñÊéò„ÄÇËøô‰∫õÈÉΩÊòØÂÜôÂü∫ÈáëÂÜôÊú¨Â≠êÈùûÂ∏∏Â•ΩÁöÑ‰∏ªÈ¢òÔºåÁÆÄÁõ¥Â∞±ÊòØÂÜô‰ΩúÁöÑÊ∫êÊ≥âÔºåÊàëÁΩóÂàó‰∏Ä‰∏ã„ÄÇ
‰ªéÁªÜËèåÁöÑËßíÂ∫¶Ôºö‰∏∫‰ªÄ‰πàÁªÜËèåÈÄâÊã©ÊÄßÁöÑÊÑüÊüìÊüê‰∫õÁªÜËÉûÔºåËÄå‰∏çÊòØÊâÄÊúâÁöÑÁªÜËÉûÔºü‰∏∫‰ªÄ‰πàÁªÜËèåÂú®‰∏Ä‰∫õÁªÜËÉû‰∏≠Ë¢´Ê∏ÖÈô§ÔºåËÄåÂú®Âè¶‰∏Ä‰∫õ‰∏≠ËøõË°åÂ¢ûÊÆñÔºüÂØÑÁîüÁöÑÁªÜËèåÊòØÂ¶Ç‰ΩïË∞ÉÊéßÂÆø‰∏ªÁªÜËÉûÔºåÂ∏ÆÂä©ÂÆÉ‰ª¨ËøõË°åÊäóÁîüÁ¥†ÊäµÊäóÁöÑÔºü
‰ªéÂÆø‰∏ªÁªÜËÉûÁöÑËßíÂ∫¶ÔºöÂ¶Ç‰ΩïÈâ¥ÂÆöÊÑüÊüìÁöÑÁªÜËÉûÂíå‚ÄúÊóÅËßÇËÄÖ‚ÄùÔºüÂÆø‰∏ªÁªÜËÉûÁöÑÂ∫îÁ≠îÂ∑ÆÂºÇÊòØÁî±‰ªÄ‰πàÂØºËá¥ÁöÑÔºüÂ¶ÇÊûúÂÆø‰∏ªÁªÜËÉûÂ±àÊúçÔºåÊòØ‰ªÄ‰πàÂÜ≥ÂÆö‰∫ÜÁªÜËÉûÊ≠ª‰∫°ÁöÑÊ®°ÂºèÔºü
ÁóÖÊØí‰∏éÂÆø‰∏ªÂÖ≥Á≥ªÁöÑÁ†îÁ©∂ËøõÂ±ïÔºà‰∏æ‰æãÔºâ ÁóÖÊØíÊÑüÊüì‰∏éÁªÜËèåÊÑüÊüì‰∏çÂêåÔºåÁóÖÊØíÂú®ÊÑüÊüìÂâçÂíåÊÑüÊüìËøáÁ®ã‰∏≠ÔºåÂÖ∂ËΩ¨ÂΩïÊú¨‰∏çÂ≠òÂú®ÂºÇË¥®ÊÄß„ÄÇÂÆÉ‰ª¨ÁöÑÂºÇË¥®ÊÄßÂ≠òÂú®‰∫éÊ†∏ÈÖ∏Â∫èÂàóÂ±ÇÈù¢„ÄÇÂÆÉ‰ª¨ÂèØËÉΩÊù•Ê∫ê‰∫éÁóÖÊØí‰∫öÁæ§ÁöÑÊ†∏Ëã∑ÈÖ∏Â§öÊÄÅÊÄßÔºåvmRNAÔºàviral mRNAÔºâÁöÑÁ™ÅÂèòÔºåÁóÖÊØíÂü∫Âõ†ÁªÑÊã∑Ë¥ùÊï∞Â∑ÆÂºÇÁ≠â„ÄÇÊúâ‰∫õÁóÖÊØíÔºåÂ¶ÇÊµÅÊÑüÁóÖÊØíÔºåÂÆÉ‰ª¨ÁöÑvmRNA‰πüÊúâÂ∞æÈÉ®Âä†poly AÁöÑÁâπÂæÅÔºåÂæóÁõä‰∫éÊ≠§ÔºåÂ∏∏ËßÑÁöÑsc-RNAseqÊñπÊ≥ïÂèØ‰ª•ÂêåÊó∂ÊçïËé∑ÁóÖÊØíRNAÔºåÂíåÂÆø‰∏ªÁªÜËÉûmRNAÂÖ±ÂêåËøõË°åÂª∫Â∫ìÂíåÊµãÂ∫è„ÄÇÈÄöËøáÊØîÂØπÁóÖÊØívmRNAÂ∫èÂàóÔºåÂèØ‰ª•Èâ¥ÂÆöÂÆø‰∏ªÁªÜËÉûÁöÑÊÑüÊüìÁä∂ÊÄÅ„ÄÇÈÄöËøáUMIËÆ°ÁÆóvmRNAÁöÑ‰∏∞Â∫¶ÔºåÂèØ‰ª•Ëé∑ÂæóÂÆø‰∏ªÁªÜËÉûÁöÑÁóÖÊØíËΩΩÈáè‰ø°ÊÅØ„ÄÇ
SteuermanÁ≠â‰∫∫ÈÄöËøáÂØπÊÑüÊüìÊµÅÊÑüÁóÖÊØí2Â§©ÂêéÁöÑÂ∞èÈº†ËÇ∫ÁªÜËÉûËøõË°åÂçïÁªÜËÉûÊµãÂ∫èÔºåÈÄöËøáËÅöÁ±ªÂØπÁªÜËÉû‰∫öÁæ§ËøõË°åÂàÜÁ±ªÔºåÁªìÂêàÁªÜËÉû‰∏≠ÁöÑvmRNAÊ∞¥Âπ≥ÔºåËé∑ÂæóÁªÜËÉûÁöÑÁóÖÊØíËΩΩÈáè‰ø°ÊÅØÔºå‰ªñ‰ª¨ÂèëÁé∞Âá†‰πéÊâÄÊúâÁ±ªÂûãÁöÑÁªÜËÉû‰∏≠ÈÉΩÂèØ‰ª•Ê£ÄÊµãÂà∞vmRNAÔºåÊ∂µÁõñ‰∫Ü62%ÁöÑ‰∏äÁöÆÁªÜËÉûÂà∞22%ÁöÑTÁªÜËÉû„ÄÇËøô‰∏ÄÂèëÁé∞ÊåëÊàò‰∫Ü‰º†ÁªüÁöÑËÆ§Áü•ÔºåËÆ§‰∏∫ÊµÅÊÑüÁóÖÊØí‰∏ªË¶ÅÊÑüÊüì‰∏äÁöÆÁªÜËÉû„ÄÇËøôÂèØËÉΩÊòØÁî±‰∫é‰ª•ÂæÄÁ†îÁ©∂ÊòØÂà©Áî®ÁóÖÊØíË°®ËææÁöÑGFPÊä•ÂëäÂü∫Âõ†ÔºåÂú®ÂÖ∂‰ªñÁ±ªÂûãÁöÑÁªÜËÉû‰∏≠Èöæ‰ª•Ê£ÄÊµãÂà∞ÈÄ†ÊàêÁöÑ„ÄÇËøôÁØáÊñáÁ´†ÂêåÊó∂‰ªé‰æßÈù¢ËØÅÊòé‰∫ÜÂà©Áî®ÂçïÁªÜËÉûËøõË°åÁóÖÂéüËèåÁ†îÁ©∂ÁöÑÂøÖË¶ÅÊÄßÔºåÂçïÁªÜËÉûÊµãÂ∫èÁõ∏ÊØî‰º†ÁªüÊäÄÊúØËÉΩÊã•ÊúâÁöÑÊõ¥È´òÁöÑÁ≤æÂ∫¶„ÄÇÁ†îÁ©∂‰∫∫ÂëòËøòÂèëÁé∞Ôºå‰∏äÁöÆÁªÜËÉûÁöÑÁóÖÊØíËΩΩÈáèÂ∑ÆÂà´ËÉΩËææÂà∞2‰∏™Êï∞ÈáèÁ∫ßÔºåËÄåÂú®ÂÖ∂‰ªñÈùû‰∏äÁöÆÁªÜËÉû‰∏≠ÁóÖÊØíËΩΩÈáèÈÄöÂ∏∏Âæà‰Ωé„ÄÇ
Âè¶Â§ñ‰∏ÄÈ°πÁ†îÁ©∂‰∏≠ÔºåRussellÂà©Áî®‰ΩìÂ§ñÊÑüÊüìÊµÅÊÑüÁóÖÊØíÁöÑ‰∏äÁöÆÁªÜËÉûËøõË°åÂçïÁªÜËÉûÊµãÂ∫è„ÄÇ‰ΩìÂ§ñËØïÈ™åÂú®Âü∫Âõ†ÁªÑÊ∞¥Âπ≥‰∏äÈôêÂÆö‰∫ÜÊµÅÊÑüÁóÖÊØíÁöÑÂçïÂÖãÈöÜÊÄßÔºåÊúÄÂ§ßÈôêÂ∫¶ÁöÑÊéßÂà∂‰∫ÜÁóÖÊØíÂºÇË¥®ÊÄßÂØºËá¥ÁöÑÊ∑∑ÊùÇÂõ†Á¥†„ÄÇ‰ªñ‰ª¨‰ªçÁÑ∂ËßÇÂØüÂà∞vmRNAÂú®ÁªÜËÉû‰πãÈó¥ËΩΩÈáèÁöÑÂ∑®Â§ßÂ∑ÆÂºÇ„ÄÇÂ§ßÈÉ®ÂàÜÊÑüÊüìÁöÑÁªÜËÉû‰ªÖÊ£ÄÊµãÂà∞&lt;0.1% vmRNAÔºåËÄåÊúâ‰∫õÁªÜËÉû‰∏≠ËÉΩÊ£ÄÊµãÂà∞50%ÁöÑvmRNA„ÄÇ‰ªñ‰ª¨ÂèëÁé∞ÁóÖÊØíËΩΩÈáèÁöÑÂ∑ÆÂºÇ‰∏éÁóÖÊØíÁöÑÂü∫Âõ†Ë°®ËææÂíåÂÆø‰∏ªÊÑüÊüìÁõ∏ÂÖ≥ÁöÑÂü∫Âõ†Ë°®ËææÂπ∂‰∏çÁõ∏ÂÖ≥ÔºåËÄåÊòØÂíåÂÆø‰∏ªÊ∞ßÂåñÂ∫îÊøÄÔºåG2-MÁªÜËÉûÂë®ÊúüÁ≠âÂü∫Âõ†ÁöÑË°®ËææÁõ∏ÂÖ≥„ÄÇËøô‰∫õÁªìÊûúËÉåÂêéÁöÑÂéüÂõ†ÊúâÂæÖËøõ‰∏ÄÊ≠•Á†îÁ©∂„ÄÇ
‰ªéËøô‰∏§ÁØáÊñáÁ´†Âá∫ÂèëÔºå‰ΩúËÄÖÂèàÊèêÂá∫‰∫Ü‰∏Ä‰∫õÊúâÂæÖË¢´Ëß£Á≠îÁöÑÈóÆÈ¢ò„ÄÇÂêåÊ†∑ÔºåÂÆÉ‰ª¨‰πüÈÄÇÂêà‰Ωú‰∏∫Êú™Êù•Á†îÁ©∂ÁöÑ‰∏ªÈ¢ò„ÄÇ‰∏∫‰ªÄ‰πàÊúâÁöÑÁªÜËÉûÊúâÈ´òÁöÑÁóÖÊØívmRNAËΩΩÈáèÔºåËÄåÂÖ∂‰ªñÁªÜËÉûÂç¥‰ºº‰πéËÉΩÈôêÂà∂ÁóÖÊØíÂü∫Âõ†Ë°®ËææÔºüvmRNAÁöÑÂ∑ÆÂºÇÂØºËá¥‰∫Ü‰ªÄ‰πàÊ†∑ÁöÑÁîüÁâ©Â≠¶ÁªìÂ±ÄÔºüÁªÜËÉû‰∏≠ÁöÑÁóÖÊØíÂ§çÂà∂ÈáèÊòØÂê¶‰ªéÊï¥ÁêÜ‰∏äÂÜ≥ÂÆöÂÆø‰∏ªÁöÑÊÑüÊüìÁªìÂ±ÄÔºüÁªÜËÉûË£ÇËß£ÂíåÊΩú‰ºèÊÑüÊüì‰πãÈó¥ÁöÑËΩ¨ÂåñÊòØÂ¶Ç‰ΩïË∞ÉÊéßÁöÑÔºü
Á†îÁ©∂ÁóÖÂéü‰Ωì‰∏∫‰ªÄ‰πà(ÊúâÊó∂ÂÄô)Áî®‰∏ç‰∫ÜÂçïÁªÜËÉûÊµãÂ∫èÔºü Â∞ΩÁÆ°sc-RNAseqÊäÄÊúØÂèëÂ±ïËøÖÁåõÔºåËé∑Âæó‰∫ÜË∂äÊù•Ë∂äÂ§öÁöÑÂ∫îÁî®Âú∫ÊôØ„ÄÇÊØîÂ¶Ç‰∏ÄÁßçÂêç‰∏∫Nuc-seqÁöÑÊñπÊ≥ïÂèØ‰ª•ÂØπÂÜ∞ÂÜªÁªÑÁªáÊ†∑Êú¨ÁöÑÁªÜËÉûÊ†∏ËøõË°åÂàÜÁ¶ªÊ†áËÆ∞Ôºå‰ªéËÄåËß£Èô§‰∫ÜÂçïÁªÜËÉûÁ†îÁ©∂Âè™ËÉΩÂÅöÊñ∞È≤úÁªÑÁªáÁöÑÈôêÂà∂„ÄÇ‰∏ÄÁßçÂØπÁªÜËèåÂü∫Âõ†ÁªÑÂàÜÊûêÁöÑÊ∂≤Êª¥Ê≥ïÂæÆÊµÅÊéßÊäÄÊúØÔºåSiC-seqÔºå‰πüÊãìÂ±ïÂà∞ÁªÜËèåÂçïÁªÜËÉûËΩ¨ÂΩïÁªÑÁöÑÂ∫îÁî®È¢ÜÂüü„ÄÇÁÑ∂ËÄå‰ºº‰πéÊäÄÊúØÁöÑËøõÊ≠•ËøòÊ≤°ÊúâÊôÆÂèäÂà∞Á†îÁ©∂ÁóÖÂéü‰Ωì-ÂÆø‰∏ªÁõ∏‰∫í‰ΩúÁî®È¢ÜÂüü„ÄÇÊúÄÁêÜÊÉ≥ÁöÑÁ†îÁ©∂ÊñπÊ°àÊòØËÉΩÂ§üÂØπÈÖçÂØπÁöÑÂÆø‰∏ªÁªÜËÉûÂèäÂÖ∂ÂÜÖÂåñÁöÑÁóÖÂéü‰ΩìËøõË°åÂêåÊó∂ÊµãÂ∫èÔºàpaired dual sc-RNAseqÔºâÔºåÂ¶ÇÂõæcÊâÄÁ§∫„ÄÇ
ËøôÁßçÁêÜÊÉ≥ÊñπÊ°à‰∏çËÉΩÂÆûÁé∞ÁöÑÂéüÂõ†‰πã‰∏ÄÊù•Ëá™‰∫éÁóÖÂéü‰ΩìÔºàÂ∞§ÂÖ∂ÊòØÁªÜËèåÔºâÂú®ÂÆø‰∏ªÁªÜËÉû‰∏≠ÁöÑË°®Ëææ‰∏∞Â∫¶Â§™‰ΩéÔºåÂπ∂‰∏î‰∏éÂÆø‰∏ªÁªÜËÉûÁöÑmRNAÂê´ÈáèÂΩ¢ÊàêÂ∑®Â§ßÁöÑÊÇ¨ÊÆä„ÄÇÈÄöËøáÊîπËøõÂª∫Â∫ìÊñπÊ≥ïÔºåÁÆóÊ≥ïÊµÅÁ®ã‰ª•ÂèäÂ¢ûÂä†ÊµãÂ∫èÊ∑±Â∫¶ÂèñÂæó‰∫Ü‰∏Ä‰∫õËøõÂ±ï„ÄÇscDual-seqÊäÄÊúØÁöÑÂºÄÂèëËÄÖÂ£∞Áß∞Ôºå‰ªñ‰ª¨Âà©Áî®Âçï‰∏™ÁªÜËÉûÂíåÂçï‰∏™ËèåÁöÑÁ∫ØÂåñÁöÑRNAËøõË°åÂª∫Â∫ìÔºåËØ•ÊñπÊ≥ïËÉΩÂ§üÊµãÂ∫èÊ£ÄÊµãÂà∞470‰∏™Ê≤ôÈó®Ê∞èËèåÁöÑËΩ¨ÂΩïÊú¨ÔºåÊèêÁ§∫Â∞ΩÁÆ°Âü∫Âõ†Ë¶ÜÁõñÂ∫¶ËæÉ‰ΩéÔºå‰ΩÜÈíàÂØπÂçï‰∏™ÁªÜËèåÁöÑÊ£ÄÊµãÊòØÂèØË°åÁöÑ„ÄÇÊ≠§Â§ñ‰ªñ‰ª¨ÂØπÂÜÖÂåñ‰∫Ü1-10‰∏™Ê≤ôÈó®Ê∞èËèåÁöÑÁªÜËÉûËøõË°åÊµãÂ∫èÔºåËé∑ÂæóÁöÑËΩ¨ÂΩïÊú¨ÈáèÂíåÁªÜËèåÊï∞ÊòæÁ§∫Âá∫‰∫ÜÊØîËæÉÂ•ΩÁöÑÁ∫øÊÄßÂÖ≥Á≥ª„ÄÇ‰ΩÜÊòØËØ•ÊäÄÊúØËøòÊ≤°ÊúâÁªèËøá‰ΩìÂÜÖÂÆûÈ™åÈ™åËØÅ„ÄÇÂú®Ëá™ÁÑ∂Áä∂ÊÄÅ‰∏ãÔºåÁªùÂ§ßÂ§öÊï∞ÁöÑÁªÜËèåÊÑüÊüìÂëàÁé∞ÂÆø‰∏ªÁªÜËÉûÂíåÁªÜËèå1 vs 1ÁöÑÁä∂ÊÄÅ„ÄÇ‰Ωé‰∏∞Â∫¶ÁöÑÁªÜËèåËΩ¨ÂΩïÊú¨ÊòØÁõÆÂâçÊäÄÊúØÂèëÂ±ïÊúÄ‰∏ªË¶ÅÁöÑÊåëÊàò„ÄÇ
dual-sc-RNAseqÁöÑÂè¶‰∏ÄÈ°πÊåëÊàò‰πüÊòØÈíàÂØπÁªÜËèåÁöÑÔºåÂÆÉÁúã‰ººÂπ≥Âá°Ôºå‰ΩÜÈùûÂ∏∏Âõ∞Èöæ„ÄÇËøô‰∏ÄÂõ∞ÈöæÊå°Âú®‰∫ÜÊµãÂ∫èÊâÄÊúâÊµÅÁ®ãÁöÑÊúÄÂâçÈù¢‚Äî‚ÄîÁªÜËèåÊ†∏ÈÖ∏ÊèêÂèñÁöÑÂõ∞Èöæ„ÄÇÁî±‰∫éÂÖ∑ÊúâÂ§πÈ¶çÔºåÁªÜËÉûÂ£ÅÁ≠âÁªÜËÉûÁªìÊûÑÔºåÁªÜËèåÁöÑË£ÇËß£ÂèòÂæóÂõ∞Èöæ„ÄÇÁâ©ÁêÜË£ÇËß£Ê≥ïÁî±‰∫éÈúÄË¶ÅÊõ¥Â§ß‰ΩìÁßØÁöÑÊ∫∂ÂâÇÊó†Ê≥ïÈÖçÂ•óÂ∏∏ËßÑÁöÑÊ∂≤Êª¥Ê≥ïÊú∫Ê¢∞ÂàÜÈÄâÔºåÂåñÂ≠¶Ë£ÇËß£Ê≥ïÂàôÂÆπÊòìÂØºËá¥RNAÈôçËß£ÊàñËÄÖÊ±°ÊüìÔºå‰ªéËÄåÊó†Ê≥ïËøõË°åÂêéÁª≠ÁöÑÂª∫Â∫ìÂÆûÈ™å„ÄÇ
ÁóÖÂéü‰ΩìRNAÈáèÂíåÂÆø‰∏ªRNAÈáè‰πãÈó¥ÊÇ¨ÊÆäÁöÑÂ∑ÆÂºÇ‰πüÊòØdual sc-RNAseqÁöÑÊåëÊàò‰πã‰∏Ä„ÄÇ‰∏ãÂõæÁ§∫ÊÑèÁúüÊ†∏ÁªÜËÉûRNAÂíåÁªÜËèåRNAÁöÑ‰∏∞Â∫¶ÂÖ≥Á≥ª„ÄÇ‰∏Ä‰∏™Âì∫‰π≥Âä®Áâ©ÁªÜËÉûÂ§ßÁ∫¶Âê´Êúâ10pgÁöÑÊÄªRNAÔºåËÄåÂçï‰∏™ÁªÜËèåÂç¥Âè™Êúâ100fgÁöÑÊÄªRNAÔºåÁ∫¶‰∏∫Âì∫‰π≥Âä®Áâ©ÁöÑÁôæÂàÜ‰πã‰∏Ä„ÄÇÂõ†Ê≠§ÔºåÂú®‰∏Ä‰∏™ÂÆø‰∏ªÁªÜËÉûÊÑüÊüì‰∏Ä‰∏™ÁªÜËèåÁöÑÊÉÖÂÜµ‰∏ãÔºåÁªÜËèåÁöÑmRNAÂÆûÈôÖÂè™Âç†ÊÄªÊèêÂèñRNA‰∏≠ÁöÑÁ∫¶0.05%„ÄÇ‰∏æ‰∏™‰æãÂ≠êÔºåÁóÖÂéüËèå‰∏≠Ë°®ËææÈáèÊúÄÂ§ßÁöÑËΩ¨ÂΩïÊú¨ÔºåÂÖ∂Âê´ÈáèÂíåÂÆø‰∏ªÁªÜËÉû‰∏≠Ë°®ËææÈáèÊúÄÂ∞èÁöÑËΩ¨ÂΩïÊú¨Áõ∏ÂΩì„ÄÇÂõ†Ê≠§ÂèØÊÉ≥ËÄåÁü•ÔºåÊèêÈ´òÊñáÂ∫ìÊûÑÂª∫ÁöÑÊïàÁéáÔºåÊòØÊèêÈ´òÂü∫Âõ†Ë¶ÜÁõñÁéáÂíåÊ£ÄÊµãÁéáÁöÑÂÖ≥ÈîÆ„ÄÇÂêåÊó∂Êàë‰ª¨ÈúÄË¶ÅÊèêÈ´òÊ£ÄÊµãÊ†∑Êú¨ÁöÑÁªÜËÉûÊï∞Êù•Ëé∑ÂæóÂÖ∑ÊúâÁªüËÆ°Â≠¶ÊÑè‰πâÁöÑÁªìÊûú„ÄÇÂ∞ΩÁÆ°ÈÄöËøáËÆ°ÁÆóÊú∫Â∑•ÂÖ∑ÂíåÁÆóÊ≥ïËÉΩÊúâÊïàÈôç‰ΩéÂàÜÊûêÊâÄÈúÄÁöÑÁªÜËÉûÊï∞ÁõÆÔºå‰ΩÜËøôÈùûÂ∏∏‰æùËµñÊâÄÁªôÂÆöÁöÑÁóÖÂéüËèåÁöÑÂü∫Âõ†ÁªÑÊ≥®Èáä‰ø°ÊÅØÁöÑÂÆåÊï¥Á®ãÂ∫¶„ÄÇ Èô§‰∫ÜÂÆø‰∏ªÁªÜËÉûRNAÂØπÁóÖÂéü‰ΩìRNAÁöÑÁ®ÄÈáä‰ΩúÁî®ÔºåÁóÖÂéü‰ΩìmRNAÁöÑÊçïËé∑ËøòÂ≠òÂú®Âè¶‰∏ÄÈ°πÊåëÊàò„ÄÇÂíåÁúüÊ†∏ÁªÜËÉû‰∏ÄÊ†∑ÔºåÁªÜËèåmRNA‰πüÂè™Âç†ÂÖ∂ÊÄªRNAÁöÑ5-10%„ÄÇÂØπ‰∫éÁúüÊ†∏ÁªÜËÉûÔºåÂÖ∂mRNAÂÖ∑Êúâploy AÂ∞æÁöÑÁâπÂæÅÔºåÂõ†Ê≠§ÈÄöËøá‰∫íË°•ÁöÑpoly TÂºïÁâ©ÂèØ‰ª•ÂæàÂ•ΩÁöÑÂØπÂÖ∂ËøõË°åÂØåÈõÜÂíåÊçïËé∑„ÄÇËÄå**ÂéüÊ†∏ÁªÜËÉûÔºàÁªÜËèåÔºâÁöÑmRNAÂπ∂Ê≤°Êúâpoly AÂ∞æ„ÄÇ**Âõ†Ê≠§Â∏∏ËßÑÂª∫Â∫ìÊó†ÂèØÈÅøÂÖçÁöÑ‰ºöÂºïÂÖ•Â§ßÈáèÁöÑrRNAÂíåtRNA„ÄÇËøô‰∏™ÈöæÈ¢òÂèØ‰ª•ÈÄöËøáÂä†Â§ßÊµãÂ∫èÊ∑±Â∫¶ÔºåÂèçÂêëÂéªÈô§rRNAÊàñËÄÖÂà©Áî®Êé¢ÈíàÊ≠£ÂêëÊçïËé∑ÁóÖÂéü‰ΩìmRNAÊù•Ëß£ÂÜ≥„ÄÇ
ÂíåÁªÜËèå‰∏çÂêåÔºåÊúâ‰∫õÁóÖÊØíÁöÑvmRNAÂÖ∑Êúâpoly AÂ∞æÁöÑÁâπÂæÅÔºåÂ¶ÇÁôªÈù©ÁÉ≠ÁóÖÊØíÔºåË•øÂ∞ºÁΩóÊ≤≥ÁóÖÊØíÂíå‰∏ôÂûãËÇùÁÇéÁóÖÊØí„ÄÇÂõ†Ê≠§Âú®Á†îÁ©∂ÂÆÉ‰ª¨ÂíåÂÆø‰∏ª‰πãÈó¥ÁöÑÂÖ≥Á≥ªÊó∂ÔºåÂ∞±Êúâ‰∫ÜÂæóÂ§©Áã¨ÂéöÁöÑ‰ºòÂäø„ÄÇ‰ΩÜÊòØÔºåËøô‰∏™ÁâπÁÇπÂπ∂‰∏çË¶ÜÁõñÊâÄÊúâÁöÑÁóÖÊØíÁßçÁ±ª„ÄÇÈô§Ê≠§‰πãÂ§ñÔºåÁ†îÁ©∂ÂèëÁé∞ÁóÖÊØíÁöÑÂü∫Âõ†ÁªÑ‰ºöÂá∫Áé∞Á±ª‰ºº‰∫éÂçïÊ†∏Ëã∑ÈÖ∏Â§öÊÄÅÊÄßÁöÑÁ™ÅÂèòÔºåËÄåËøôÁßçÂæÆÂ∞èÁöÑÂèòÂºÇ‰ºöÂΩ±ÂìçÂÆø‰∏ªÁöÑÂ∫îÁ≠î„ÄÇÂõ†Ê≠§Âú®Á†îÁ©∂ÁóÖÊØíÊó∂ÈúÄË¶ÅÊúâÊõ¥Â•ΩÁöÑËÆ°ÁÆóÂ∑•ÂÖ∑ËÉΩÂ§üÂú®ÂçïÁªÜËÉûÊ∞¥Âπ≥ÂéªÂàÜÊûêÁóÖÊØíÂü∫Âõ†ÁªÑÂ§öÊ†∑ÊÄß‰∏éÂÆø‰∏ªÂ∫îÁ≠î‰πãÈó¥ÁöÑÂÖ≥Á≥ª„ÄÇ
ÊÄªÁªì ÂçïÁªÜËÉûRNAseqÈù©ÂëΩÊãìÂÆΩ‰∫ÜÊàë‰ª¨ÂØπÁªÜËÉûÂºÇË¥®ÊÄßÁöÑÁêÜËß£ÔºåÂπ∂‰∏îËÆ§ËØÜÂà∞Á®ÄÊúâÁªÜËÉûÁ±ªÂûãÂú®ÊâÄÊúâÁîüÁâ©Â≠¶È¢ÜÂüüÔºàÂåÖÊã¨ÂÆø‰∏ª- ÁóÖÂéü‰ΩìÁõ∏‰∫í‰ΩúÁî®ÔºâÁöÑÂ≠òÂú®ÂíåÈáçË¶ÅÊÄß„ÄÇ ËøôÁØáÁªºËø∞Âº∫Ë∞É‰∫ÜÂÆø‰∏ªÂíåÁóÖÂéü‰ΩìÂêÑËá™ÁöÑÂºÇË¥®ÊÄßÂØºËá¥‰∫Ü‰ªñ‰ª¨ÈÅ≠ÈÅáÂêéÁöÑÊó†Êï∞ÂèØËÉΩÁöÑÁªìÊûú„ÄÇ ÂçïÁªÜËÉûËßÜËßíÁ†îÁ©∂ÁªÜËÉûË°å‰∏∫Â∞ÜÊòØÊàë‰ª¨Á†îÁ©∂Â§çÊùÇÁîüÁêÜÂíåÁóÖÁêÜÁä∂ÊÄÅ‰∏ãÁöÑÁîüÁâ©Â≠¶Áé∞Ë±°Êú™Êù•‰∏ªË¶ÅÁöÑÁ†îÁ©∂ÊâãÊÆµ„ÄÇ]]></description>
</item>
<item>
    <title>„Äêbioinfo„Äë-Q&amp;A-60</title>
    <link>https://uioqps.github.io/bioinfo-q-a-60/</link>
    <pubDate>Fri, 21 Feb 2020 22:03:10 &#43;0000</pubDate>
    <author>Milky</author>
    <guid>https://uioqps.github.io/bioinfo-q-a-60/</guid>
    <description><![CDATA[Êâ´ÊèèÊé¢Á¥¢Âü∫Âõ†ÂÖ®ÈÉ®Âå∫ÂüüSNVÁöÑÂäüËÉΩÂΩ±Âìç Êé¢Á¥¢BRCA1Âü∫Âõ†ÂÖ®ÈÉ®ÂèØËÉΩÁöÑÁ™ÅÂèòÁöÑÂäüËÉΩ Accurate classification of BRCA1 variants with saturation genome editing Â≠óÈù¢ÊÑèÊÄùÊòØÊé¢Á¥¢‰∫ÜBRCA1Âü∫Âõ†‰∏äÈù¢ÁöÑÂÖ®ÈÉ®ÂèØËÉΩÁöÑÁ™ÅÂèò‰ΩçÁÇπÁöÑÁîüÁâ©Â≠¶ÊÑè‰πâÔºå‰ΩÜ‰∫ãÂÆû‰∏äÂè™ÊòØÊé¢Á¥¢‰∫Ü96.5% of all possible single-nucleotide variants (SNVs) in 13 exons that encode functionally critical domains of BRCA1. ÂÖ∑‰ΩìÊï∞ÁõÆÂ¶Ç‰∏ãÔºö
‰∏çËøáËøô‰∏™ÊñπÊ≥ïÁöÑÁ°ÆÊòØÂæàÂ§ßÁöÑÂàõÊñ∞ÔºåÂè™‰∏çËøáÂ∑•‰ΩúÈáèÂ§™Â§ßÔºåÂ¶ÇÊûúÊÉ≥ÁúüÊ≠£ÁöÑÂÖ®Âü∫Âõ†ÁªÑÂÖ®ÈÉ®‰ΩçÁÇπÈÉΩÊé¢Á¥¢‰∏ÄÈÅç„ÄÇ
ËÉåÊôØÁü•ËØÜ BRCA1Âü∫Âõ† BRCA1ÊòØ‰∏ÄÁßç‰∫∫‰ΩìËÇøÁò§ÊäëÂà∂Âü∫Âõ†ÔºåBRCA1Â§±ÂéªÂäüËÉΩÁöÑÁ™ÅÂèò‰∏éÊòìÊÇ£Êó©ÂèëÂûã‰π≥ËÖ∫ÁôåÂíåÂçµÂ∑¢ÁôåÊúâÂÖ≥„ÄÇËôΩÁÑ∂Â∑≤ÂèëÁé∞ÁöÑBRCA1Âü∫Âõ†ÂèòÂºÇÊúâÊï∞ÂçÉÁßçÔºå‰ΩÜËÆ∏Â§öÈÉΩË¢´Âàó‰∏∫‚ÄúÊÑè‰πâÊú™ÊòéÁöÑÂèòÂºÇ‚ÄùÔºåÁªôÊÇ£ÁôåÈ£éÈô©ËØÑ‰º∞Â∏¶Êù•‰∫ÜÂ∑®Â§ßÊåëÊàò„ÄÇ
variants of uncertain significance (VUS) Âü∫Âõ†Á™ÅÂèòÊ∫ê‰∫éÁªÜËÉûÂàÜË£ÇÔºå‰ΩÜÊòØÂπ∂‰∏çÊòØÊâÄÊúâÁöÑÂèòÂºÇÈÉΩ‰∏éÁñæÁóÖÊúâÂÖ≥ÔºåÂÆÉ‰ª¨Ë¢´ÂàÜÊàê‚ÄúËâØÊÄß‚Äù„ÄÅ‚ÄúÂèØËÉΩËâØÊÄß‚Äù‚Äú‰∏çÁ°ÆÂÆöÈáçË¶ÅÊÄßÁöÑÂèòÂºÇ‚Äù„ÄÅ‚ÄúÂèØËÉΩËá¥ÁóÖ‚ÄùÂíå‚ÄúËá¥ÁóÖÊÄßÁöÑ‚Äù„ÄÇ
ÊÑè‰πâ‰∏çÊòéÁ°ÆÁöÑÁ™ÅÂèòÔºàÂç≥VUSÔºâÔºåÂåÖÊã¨Âü∫Âõ†‰∏é‰ª•ÂèäÂèëË°®ÁöÑDNAÂü∫Âõ†ÊúâÁùÄ‰∏çÂêåÂ∫èÂàóÁöÑÂü∫Âõ†ÔºåÂπ∂‰∏îÊó¢‰∏çËÉΩÂΩíÂÖ•ÊúâÂÆ≥Á™ÅÂèòÁöÑÁ±ªÂà´„ÄÅ‰πü‰∏çËÉΩÂΩíÂÖ•Êó†ÂÆ≥Á™ÅÂèòÁöÑÁ±ªÂà´„ÄÇ
VUSÊä•ÂëäËß£ËØªÁöÑÈöæÁÇπÈ¶ñÂÖàÂ∞±ÊòØVUSÈùûÂ∏∏Èöæ‰ª•ÂàÜÁ±ª„ÄÇËøôÊòØÂõ†‰∏∫Ôºö
1 2  È¶ñÂÖàÔºåÊòØÁõÆÂâçÂπ∂Êó†‰∏ÄËá¥ÁöÑÊä•ÂëäÂÜÖÂÆπÂíåÊ†ºÂºèÔºöÊúâÁöÑÊä•Âëä‰∫ÜÂèòÂºÇ‰ΩÜÊòØÂπ∂Êó†Ëß£Èáä„ÄÅÊúâÁöÑ‰ΩøÁî®‰∫ÜÂ±ÄÈÉ®Âú∞Âå∫ÁöÑÊåáÂçó„ÄÇ ÂÖ∂Ê¨°ÔºåÊòØÊàë‰ª¨ÈúÄË¶ÅÊõ¥Â§öÁöÑËØÅÊçÆÊù•Â∏ÆÂä©Êàë‰ª¨Á°ÆÂÆöÊüê‰∫õÁ™ÅÂèòÁ°ÆÂÆûÊòØ‰∏éÁôåÁóáÁõ∏ÂÖ≥ÁöÑ„ÄÇ   ÁõÆÂâçÊúâ2ÁßçÂÆûÈ™åÊñπÊ°àÊù•ËØÑ‰ª∑‰∏Ä‰∏™VUSÔºå‰ΩÜÊòØÈÉΩÂ§™‰ΩéÊïà„ÄÇ
ÁªÜËÉûÁ≥ªHAP1 ÁâπÊÆäÁöÑÁªÜËÉûÁ≥ªHAP1„ÄÇÂú®ËøôÁßçÁªÜËÉûÁ≥ªÈáåÔºå‰∏ÄÊó¶BRCA1ËõãÁôΩÂ§±ÂéªÂÖ∂Â∫îÊúâÁöÑÂäüËÉΩÔºåÁªÜËÉûÂ∞±‰ºöÊ≠ª‰∫°„ÄÇ Âü∫‰∫éÊ≠§ÔºåÁæéÂõΩÂçéÁõõÈ°øÂ§ßÂ≠¶ÁöÑJay ShendureÂèäÂêå‰∫ãËøêÁî®Âü∫Âõ†ÁªÑÁºñËæëÊäÄÊúØÔºåÂØπBRCA1Âü∫Âõ†ÂäüËÉΩËá≥ÂÖ≥ÈáçË¶ÅÁöÑ13‰∏™Â§ñÊòæÂ≠ê‰∏äÁöÑËøë4000ÁßçÂçïÊ†∏Ëã∑ÈÖ∏ÂèòÂºÇ ÁöÑÂäüËÉΩËøõË°å‰∫ÜËØÑ‰º∞ÔºåÂπ∂Âú®2000‰∏á‰∏™‰∫∫Á±ªÂçïÂÄç‰Ωì HAP1 ÁªÜËÉû‰∏≠ËøõË°å‰∫ÜÂêéÁª≠ÁªÜËÉûÂ≠òÊ¥ªÁéáÊµãÂÆö „ÄÇ
saturation genome editing (SGE) ‰ªñ‰ª¨ÊØèÊ¨°Âú®2000‰∏á‰∏™ÁªÜËÉûÂÜÖÔºåÂØπ‰∏ÄÊï¥ÊÆµÂ§ñÊòæÂ≠êËøõË°åÂü∫Âõ†ÁºñËæë„ÄÇÈöèÂêéÔºåÁ†îÁ©∂‰∫∫Âëò‰ª¨ÂÖàËÆ©Ëøô‰∫õÁªÜËÉûÁîüÈïø11Â§©ÔºåÂÜçÂÅöÂêéÁª≠ÁöÑÂàÜÊûê„ÄÇÂ¶ÇÊûúÁî±‰∫éÊüê‰∏™ÁâπÂÆöÁ™ÅÂèòÂØºËá¥BRCA1Â§±ÂéªÂÖ∂ÂäüËÉΩÔºåÁõ∏Â∫îÁöÑÁªÜËÉûÂ∞±‰ºöÊ≠ª‰∫°ÔºåÂêéÁª≠ÂàÜÊûê‰∏≠‰πüÂ∞±Êõ¥ÈöæÊâæÂà∞ËøôÁßçÁâπÂÆöÁ™ÅÂèòÁöÑÂ≠òÂú®„ÄÇ
RNA score Function score ‰ΩúËÄÖÁöÑËÆ°ÁÆóÁªìÊûúÊèê‰æõÁôªËÆ∞ÂêéÁöÑ‰∏ãËΩΩÔºöhttps://sge.gs.washington.edu/BRCA1/ ËÆ°ÁÆóÊñπÊ≥ïÂ¶Ç‰∏ãÔºö
1 2 3  we first calculated the log2ratio of the frequency of a SNV on day 11 to its frequency in the plasmid library.]]></description>
</item>
<item>
    <title>„Äêbioinfo„Äë-Q&amp;A-59</title>
    <link>https://uioqps.github.io/bioinfo-q-a-59/</link>
    <pubDate>Fri, 21 Feb 2020 22:03:06 &#43;0000</pubDate>
    <author>Milky</author>
    <guid>https://uioqps.github.io/bioinfo-q-a-59/</guid>
    <description><![CDATA[ËÇùÁôåÂ§çÂèëÁöÑCpGÁî≤Âü∫Âåñ‰ø°Âè∑ÁâπÂæÅ ÊùÇÂøóÊòØ JOURNAL OF CLINICAL ONCOLOGY ÂΩ±ÂìçÂõ†Â≠ê26.303 Ôºå ÊñáÁ´†ÊòØ CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study
1 2  LASSO, Least Absolute Shrinkage and Selector Operation; SVM-RFE, Support Vector Machine-Recursive Feature Elimination;   ÂâçÈù¢Êàë‰ª¨ËÆ≤Ëß£‰∫Ü‰∏ÄÁØá2013Âπ¥Â§öÁªÑÂ≠¶Êï∞ÊçÆÊé¢Á¥¢‰π≥ËÖ∫ÁôåÁªÜËÉûÁ≥ªËçØÁâ©ÊïèÊÑüÊÄß‰ΩøÁî®ÁöÑ‰πüÊòØ‰∏§‰∏™Êú∫Âô®Â≠¶‰π†ÁÆóÊ≥ïÔºå‰∏çËøáÊòØLS-SVMÂíåRFÔºå‰ΩÜÊòØ‰πüÊúâÂÄüÈâ¥ÊÑè‰πâ„ÄÇ
ËØæÈ¢òËÆæËÆ° Ëá™Â∑±ÁöÑ450KÁî≤Âü∫ÂåñËäØÁâáÊï∞ÊçÆ‰∏ä‰º†Âà∞‰∫ÜÔºöGSE75041
Êú¨È°πÁõÆÂÖ±Á∫≥ÂÖ• 576 patients with Early-stage hepatocellular carcinoma (E-HCC) ÔºåÂÖ∂‰∏≠
 66 tumor samples were analyzed using the Illumina Methylation 450k Beadchip. internal cohort (n = 141) and two external cohorts (n = 191 and n =104).]]></description>
</item>
<item>
    <title>„Äêbioinfo„Äë-Q&amp;A-58</title>
    <link>https://uioqps.github.io/bioinfo-q-a-58/</link>
    <pubDate>Fri, 21 Feb 2020 22:03:03 &#43;0000</pubDate>
    <author>Milky</author>
    <guid>https://uioqps.github.io/bioinfo-q-a-58/</guid>
    <description><![CDATA[Â§öÁªÑÂ≠¶Êé¢Á¥¢‰∏çÂêåÂô®ÂÆòÁöÑÂ∞èÁªÜËÉûÁôåÁóáËµ∑Ê∫ê ÊñáÁ´†ÊòØÔºöReprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage Â∞èÁªÜËÉûÁôåÁóáÈáåÈù¢ÊúÄÂá∫ÂêçÁöÑÂ∫îËØ•ÊòØÂ∞èÁªÜËÉûËÇ∫Áôå(SCLC)‰∫ÜÔºåÊÅ∂ÊÄßÂ∫¶È´ò,È¢ÑÂêéÂ∑Æ,Ê≤ªÁñó‰∏äËøõÂ±ï‰πüÊØîËæÉÂ∞ë„ÄÇÂ∞èÁªÜËÉûËÇ∫ÁôåÂ§ßÁ∫¶Âç†ÊâÄÊúâËÇ∫ÁôåÁöÑ15%,ÊØèÂπ¥ÂÖ®ÂõΩÊúâÂçÅÂá†‰∏áÊñ∞ÂèëÁöÑÂ∞èÁªÜËÉûËÇ∫ÁôåÊÇ£ËÄÖ,ÂÖ∂‰∏≠ÁªùÂ§ßÂ§öÊï∞ÊÇ£ËÄÖËØäÊñ≠ÁöÑÊó∂ÂÄôÂ∞±Â∑≤ÁªèÊòØÊôöÊúü„ÄÇÊâÄ‰ª•ÈíàÂØπÂÆÉÁöÑÁ†îÁ©∂ÔºåÂ∞±ÊúâÁÇπÁ±ª‰ºº‰∫é‰π≥ËÖ∫ÁôåÈáåÈù¢ÁöÑTNBC‰∏ÄÊ†∑„ÄÇ
ÊúâË∂£ÁöÑÊòØÔºåÂ§ßÈÉ®ÂàÜÂÖ¨‰ºóÂè∑Ëß£ËØªËøôÁØáÊñáÁ´†ÁöÑÊ†áÈ¢òÈÉΩ‰æßÈáç‰∫éÊåáÂá∫ÔºöScience:Â¶Ç‰ΩïÂ∞ÜÂÅ•Â∫∑ÁªÜËÉûÁôåÂåñ?Âè™ÈúÄ‰∫î‰∏™Âü∫Âõ†
‰∏Ä‰∫õÂêçËØçÔºö
1 2 3 4 5 6 7  small cell neuroendocrine carcinoma (SCNC) reprogrammed prostate and lung SCNCs small cell prostate cancer (SCPC) small cell lung cancer (SCLC) euroendocrine prostate cancer (NEPC) poorly differentiated prostate adenocarcinoma (PrAd) large cell prostate carcinoma   ÂæàÂ§ö‰∏çÂêåÂô®ÂÆòÁöÑÁôåÁóá‰ºöÂèëÂ±ïÊàêÂÖ∑ÊúâÂæàÂº∫‰æµÁï•ÊÄßÁöÑÂ∞èÁªÜËÉûÁôåÔºå‰πüÁß∞‰∏∫Â∞èÁªÜËÉûÁ•ûÁªèÂÜÖÂàÜÊ≥åÁôåÔºàSCNCÔºâÊù•ÊäµÂà∂Ê≤ªÁñó„ÄÇ‰∏çÂêåÂô®ÂÆòÁöÑÁôåÁóáÁ±ªÂûãÊòØÂê¶ÈÄöËøáÁõ∏ÂêåÈÄîÂæÑËΩ¨ÂèòÊàêSCNCÁªÜËÉûËøò‰∏çÊ∏ÖÊ•ö„ÄÇËÇ∫Áôå„ÄÅÂâçÂàóËÖ∫Áôå„ÄÅËÜÄËÉ±ÁôåÂíåÂÖ∂‰ªñÁªÑÁªáÁöÑÂ∞èÁªÜËÉûÁôåÂú®ÂêçÁß∞‰∏äÊòØÁõ∏‰ººÁöÑÔºå‰ΩÜÊòØ‰∏¥Â∫äÂåªÁîüÈÄöÂ∏∏ÊääÂÆÉ‰ª¨ÂΩì‰Ωú‰∏çÂêåÁöÑÂÆû‰ΩìÊù•Ê≤ªÁñóÔºåÁÑ∂ËÄåÔºåÂú®ËøáÂéªÁöÑÂá†Âπ¥ÈáåÔºåÁ†îÁ©∂ËÄÖ‰ª¨ÈÄêÊ∏êÂºÄÂßãËÆ§ËØÜÂà∞ÁôåÁóáÊúâÁõ∏‰ºº‰πãÂ§Ñ„ÄÇ
 ÂÖ≥ÈîÆÂèëÁé∞ÔºöÂâçÂàóËÖ∫ÂíåËÇ∫ÁªÜËÉûÂú®ÂÅ•Â∫∑Êó∂ÊúâÁùÄÈùûÂ∏∏‰∏çÂêåÁöÑÂü∫Âõ†Ë°®ËææÊ®°ÂºèÔºå‰ΩÜÊòØÂΩìÂÆÉ‰ª¨ËΩ¨ÂåñÊàêÂ∞èÁªÜËÉûÁôåÊó∂ÔºåÂá†‰πéÂÖ∑ÊúâÁõ∏ÂêåÁöÑÊ®°Âºè„ÄÇÁ†îÁ©∂Ë°®ÊòéÔºå‰∏çÂêåÁ±ªÂûãÁöÑÂ∞èÁªÜËÉûÁò§ÁöÑÊºîÂèòÁõ∏‰ººÔºåÂç≥‰ΩøÂÆÉ‰ª¨Êù•Ëá™‰∏çÂêåÁöÑÂô®ÂÆò„ÄÇ  3ÁßçngsÁªÑÂ≠¶ÊµãÂ∫èÊï∞ÊçÆ ÈÄöËøáÂ∞ÜÂ∏¶Êúâ‰∫î‰∏™Âü∫Âõ†ÁöÑ‰∫∫Á±ªÂâçÂàóËÖ∫ÁªÜËÉû(ÁªüÁß∞‰∏∫PARCB)ÁßªÊ§çÂà∞Â∞èÈº†‰ΩìÂÜÖÔºåÊé¢Á¥¢‰∫ÜÁôåÁóáÁ±ªÂûã‰πãÈó¥ÁöÑÊΩúÂú®Áõ∏‰ºº‰πãÂ§Ñ„ÄÇÂΩìËøô‰∫õÁªÜËÉûÂú®Â∞èÈº†‰ΩìÂÜÖÁîüÈïøÊó∂ÔºåÂÆÉ‰ª¨ÊòæÁ§∫Âá∫‰∫∫Á±ªÂ∞èÁªÜËÉûÁ•ûÁªèÂÜÖÂàÜÊ≥åÁôåÁöÑÁã¨ÁâπÁâπÂæÅÔºåÂü∫Âõ†Â¶Ç‰∏ãÔºõ
‰∏çÂêåÂü∫Âõ†ÁöÑÁªÑÂêàÁöÑÂàÜÁªÑÂ∞±ÂèØ‰ª•ÈÄöËøáNGSÊâãÊÆµÊù•Êé¢Á¥¢‰ªñ‰ª¨ÁöÑÂ∑ÆÂºÇ„ÄÇ
GSE118204 ÂåÖÂê´Âè¶Â§ñ3‰∏™GSEÊï∞ÊçÆÈõÜÔºåÂàÜÂà´ÊòØRNA-seqÔºåWhole Exome-seqÔºåATAC-seq
1  gseinfo GSE118204Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage (ATAC-seq)GSE118205Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage (Whole Exome-seq)GSE118206Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage (RNA-seq)GSE118207PARCB Project: Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage   ‰ΩÜÊòØ‰ΩúËÄÖÁöÑÂàÜÊûêÁªìÊûú‰∏ªË¶ÅÈõÜ‰∏≠‰∫é RNA-seqÂíåATAC-seqÔºåÁúã‰∫ÜÁúãÂ∫îËØ•ÊòØWhole Exome-seqÊï∞ÊçÆÊòØÊ≤°ÊúâÈÖçÂØπÊ≠£Â∏∏ÁªÑÁªáÊµãÂ∫èÁªìÊûúÊù•ËæÖÂä©ÂØªÊâæsomaticÁöÑmutation‰ø°ÊÅØ„ÄÇ]]></description>
</item>
<item>
    <title>„Äêbioinfo„Äë-Q&amp;A-57</title>
    <link>https://uioqps.github.io/bioinfo-q-a-57/</link>
    <pubDate>Fri, 21 Feb 2020 22:02:59 &#43;0000</pubDate>
    <author>Milky</author>
    <guid>https://uioqps.github.io/bioinfo-q-a-57/</guid>
    <description><![CDATA[‰π≥ËÖ∫ÁôåÁöÑÁ±ªÂô®ÂÆòÁ†îÁ©∂ Êú¨Á†îÁ©∂ÊòØ‰π≥ËÖ∫ÁôåÈ¢ÜÂüüÁöÑÁ¨¨‰∏Ä‰∏™Á±ªÂô®ÂÆòÁ†îÁ©∂ A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
Á†îÁ©∂ËÄÖÊî∂ÈõÜ‰∫Ü Ë∂ÖËøá150‰æã‰π≥ËÖ∫ÁôåÊÇ£ËÄÖÊ†∑ÂìÅÔºåÁÑ∂ÂêéÂ£∞Áß∞ÂÖ∂Âõ¢ÈòüÊàêÂäüÁöÑÂà∂‰Ωú‰∫ÜË∂ÖËøá100‰∏™Á±ªÂô®ÂÆò„ÄÇ
From 155 tumors, we established 95 BC organoid lines that readily expanded. ËÄå‰∏îNGSÊï∞ÊçÆÂàÜÊûêÁªìÊûúË°®ÊòéÁ±ªÂô®ÂÆòÊØîËæÉÂ•ΩÁöÑ‰øùÁïôÂÖ∂ÈÖçÂØπËÇøÁò§Ê†∑ÂìÅÁöÑCNVÂíåSNVÁâπÂæÅ„ÄÇ
ÂàÜÊûêÊµÅÁ®ãÂæàÂ∏∏ËßÑÔºåÂ∞±ÊòØÊÉ≥ÂäûÊ≥ïÊèê‰æõorganoidsÁöÑÊàêÂäüÁéáÔºåÂπ∂‰∏î‰ªéÂêÑ‰∏™ËßíÂ∫¶Êù•ËØÅÊòéÔºö
1 2 3 4  histology whole genome DNA sequencing (WGS) RNA sequencing (RNA-seq) drug testing   ÂÖ®Âü∫Âõ†ÁªÑÂàÜÊûê ‰∏äÊ∏∏ÂàÜÊûêÂæóÂà∞somaticÁöÑSNVsÊµÅÁ®ãÊàëÂú®Áîü‰ø°ÊäÄËÉΩÊ†ëÂ§öÊ¨°‰ªãÁªçËøáÔºåËøôÈáå‰ΩúËÄÖÈááÂèñÁöÑÊòØÂÖ∂ÂÆûÈ™åÂÆ§ÂÜÖÈÉ®Êï∞ÊçÆÂàÜÊûêÊµÅÁ®ãÔºå‰ΩÜÊòØÂ§ßÂêåÂ∞èÂºÇ„ÄÇÊï∞ÊçÆ‰∏ä‰º†Âà∞‰∫Ü EGAS00001002158 ÈúÄË¶ÅÁî≥ËØ∑ÊéàÊùÉÊâçËÉΩ‰∏ãËΩΩ„ÄÇ
Êï∞ÊçÆÂàÜÊûêÊµÅÁ®ãËØ¶ÁªÜÊèèËø∞Â¶Ç‰∏ãÔºö
ÂÖ®Âü∫Âõ†ÁªÑÊµãÂ∫èÊï∞ÊçÆÂæóÂà∞ÁöÑCNV‰ø°ÊÅØÔºåÊúâ‰∏§‰∏™ÂåπÈÖçÊØîËæÉÂ•ΩÁöÑorganoidsÂ¶Ç‰∏ãÔºö
‰∫ãÂÆû‰∏äËøôÊ†∑ÁöÑÂ±ïÁé∞ÊñπÂºèÂπ∂‰∏çÂ•ΩÔºåÈúÄË¶Å‰ªîÁªÜÁúã‰∏§‰∏™CNVÂõæÁöÑÁõ∏‰ººÊÄßÔºåÂ¶ÇÊûú‰ªîÁªÜÁúãÔºåÂÖ∂ÂÆûÂæàÂ§öÂú∞ÊñπÂπ∂‰∏çÂåπÈÖç„ÄÇ
ÂÖ∂ÂÆÉÁöÑÈÖçÂØπÁöÑÁ±ªÂô®ÂÆòÂ∞±‰∏çÂÄº‰∏ÄÊèêÔºåÊâÄ‰ª•‰ΩúËÄÖ‰ªÖ‰ªÖÊòØÊåëÈÄâÈÉ®ÂàÜÂü∫Âõ†Êù•ÁúãorganoidsÂèäÂÖ∂primaryËÇøÁò§ÁöÑCNVÁöÑÂåπÈÖçÊÉÖÂÜµÔºåÂ¶Ç‰∏ãÔºö
Âç≥‰ΩøÊòØ‰ΩúËÄÖÂè™ÊåëÈÄâÈÉ®ÂàÜÂü∫Âõ†Êù•Â±ïÁ§∫CNVÁöÑÂåπÈÖçÊÄßÔºåËÄå‰∏î‰ΩúËÄÖ‰πüÂ£∞Áß∞ÂåπÈÖçÊÄßÂæàÂ•ΩÔºåÂèØÊòØ‰ªñÂπ∂Ê≤°ÊúâÁªô‰ªÄ‰πàÁªüËÆ°Â≠¶ÊåáÊ†áËØÅÊòéÂåπÈÖçÂæàÂ•Ω„ÄÇ
ÂØπSNV‰πüÊòØÂ¶ÇÊ≠§ÔºåÊåëÈÄâÈÉ®ÂàÜÂü∫Âõ†ÁßÄÔºåÂ¶Ç‰∏ãÔºö
ÂèØ‰ª•ËÇØÂÆöÁöÑÊòØorganoidsÁöÑSNV‰∏çÂèØËÉΩÁôæÂàÜÁôæ‰∏éÂÖ∂primaryËÇøÁò§ÁöÑsomatic SNV‰∏ÄËá¥ÔºåÊâÄ‰ª•‰ΩúËÄÖÊØîËæÉÁöÑÊòØÁ™ÅÂèòÁöÑÊÄªÊï∞Ôºå‰ª•ÂèäÁ™ÅÂèòÁöÑÁâπÂæÅÈ¢ëË∞±ÔºåÂ¶Ç‰∏ãÔºö
‰ªéDNAÂèòÂºÇÊÉÖÂÜµÁúãorganoids‰∏çÂêåÂüπÂÖªÊó∂ÊúüÁöÑÊÉÖÂÜµ ÂêåÊ†∑ÔºåÈ¶ñÂÖàÊòØCNVÊÉÖÂÜµÔºö
ÂèØ‰ª•ÁúãÂà∞ÊòØÁ±ª‰ººÁöÑÔºåÂèØ‰ª•ÂæóÂá∫ÁªìÊûúorganoids‰øùÁïô‰∫ÜÂÖ∂ËÇøÁò§ÁöÑÂàÜÂ≠êÁâπÊÄß„ÄÇ
ÁÑ∂ÂêéÁúãSNVÁöÑÔºåÈ¶ñÂÖàÊòØÁ™ÅÂèòÊï∞ÈáèÂíå6Á™ÅÂèòÈ¢ëË∞±Â¶Ç‰∏ãÔºö
ÁÑ∂ÂêéÁúã96Á™ÅÂèòÈ¢ëË∞±Ôºö
ÊúÄÂêé‰ΩúËÄÖÁöÑÁªìËÆ∫Â∞±ÊòØorganoids‰øùÁïô‰∫ÜÂÖ∂ËÇøÁò§ÁöÑÂàÜÂ≠êÁâπÊÄßÔºåËÄå‰∏îÂüπÂÖªÊó∂Èó¥ÂΩ±Âìç‰∏çÂ§ß„ÄÇ
ËΩ¨ÂΩïÁªÑÊï∞ÊçÆÂàÜÊûê È¶ñÂÖàÁúã‰ΩúËÄÖÁöÑËΩ¨ÂΩïÁªÑÊï∞ÊçÆÂ§ÑÁêÜÊñπÊ≥ïÔºö
ËΩ¨ÂΩïÁªÑË°®ËææÈáèÁü©ÈòµÁöÑÂà©Áî®ÁéáÊØîËæÉ‰ΩéÔºåÂü∫Êú¨‰∏äÂ∞±Áúã‰∫ÜÁúãÁõ∏ÂÖ≥ÊÄßÔºåËøò‰∏çÂ¶ÇPCAÂõæÊù•ÁöÑÁõ¥ËßÇÔºåËÄå‰∏î‰πüÂ∞±ÊòØË∑üTCGAÁöÑ‰π≥ËÖ∫ÁôåÁ≥ÖÂêàÂú®‰∏ÄËµ∑ËøõË°åËÅöÁ±ªÔºåÂ¶Ç‰∏ãÔºõ]]></description>
</item>
<item>
    <title>„Äêbioinfo„Äë-Q&amp;A-56</title>
    <link>https://uioqps.github.io/bioinfo-q-a-56/</link>
    <pubDate>Fri, 21 Feb 2020 22:02:55 &#43;0000</pubDate>
    <author>Milky</author>
    <guid>https://uioqps.github.io/bioinfo-q-a-56/</guid>
    <description><![CDATA[Â§öÊó∂Èó¥ÁÇπÂèñÊ†∑ËΩ¨ÂΩïÁªÑÊï∞ÊçÆ Êó∂Èó¥Â∫èÂàóË°®ËææÁü©ÈòµÊè≠Á§∫ËÇøÁò§ËΩ¨ÁßªÁöÑÂä®ÊÄÅËøáÁ®ã ËÇùÁôåÂæàÂèØÊÄïÔºåÂ∞§ÂÖ∂ÊòØËΩ¨ÁßªÂêéÔºåÂæàÂ§öÂÖ≥‰∫éÂÖ∂ËΩ¨ÁßªÂâçÂêéÂØπÊØîÁöÑÁ†îÁ©∂Ôºå‰ΩÜÊòØÁº∫‰πè‰∏≠Èó¥ËøáÁ®ãÊï∞ÊçÆÔºåÁâπÂà´ÊòØËΩ¨Áßª‰∏¥ÁïåÁÇπ„ÄÇ
‰ΩúËÄÖÈÄöËøáËÇùÁôåÊ®°ÂûãÔºåÂú®‰∏çÂêåÊó∂Èó¥ÁÇπÂèñÊ†∑ÂÅöËäØÁâáËΩ¨ÂΩïÁªÑÔºåËØïÂõæÂàÜÊûê non-metastatic (or normal) and pre-metastatic (or critical) Ëøô‰∏§ÁßçÁä∂ÊÄÅÂå∫Âà´„ÄÇÈ°∫Âà©ÊâæÂà∞‰∫Ü‰∏¥ÁïåÁÇπÂèäÂÖ∂Áõ∏ÂÖ≥Ë∞ÉÊéßÁΩëÁªúÔºåËÄå‰∏îËøòÈáçÁÇπÂàÜÊûê‰∫ÜÂÖ∂‰∏≠‰∏Ä‰∏™ÁΩëÁªúÁöÑÊúÄÈáçË¶ÅÁöÑËäÇÁÇπÂü∫Âõ†ÔºöCALML3
To discover early warning signals of pulmonary metastasis in HCC, we analysed time-series gene expression data in the spontaneous pulmonary metastasis mouse HCCLM3-RFP model with our novel dynamic network biomarker (DNB) method.
ÊûÑÂª∫‰∫Ü xenograft HCCLM3-RFP mice Ôºå 20Âè™Â∞èÈº†ÂàÜÊàê4ÁªÑÔºåÂç≥4‰∏™Êó∂Èó¥ÁÇπ(W2, W3, W4, W5)ÂèñÊ†∑„ÄÇ
ÊâæÂ∑ÆÂºÇÂü∫Âõ† ‰ΩøÁî®ÁöÑÊòØ‰º†ÁªüÁöÑTÊ£ÄÈ™åÔºåÂØπ‰ªªÊÑè‰∏§ÁªÑÁöÑÁªÑÂêàÊâæÂ∑ÆÂºÇÔºåÊúÄÂêéÂêàÂπ∂Êàê13,247 ‰∏™Â∑ÆÂºÇÂü∫Âõ†ÂàóË°®ÔºåÂπ∂‰∏îÁªòÂà∂ÁÉ≠ÂõæÂ¶Ç‰∏ãÔºö
Êó∂Èó¥Â∫èÂàóÂü∫Âõ†ÈõÜ ‰ΩøÁî®ÁöÑÊòØRÂåÖMfuzzÊääÂ∑ÆÂºÇÂàÜÊûêÂæóÂà∞ÁöÑ13,247 ‰∏™ÁªüËÆ°Â≠¶ÊòæËëóÂ∑ÆÂºÇÂü∫Âõ†Ê†πÊçÆË°®ËææÊ®°ÂºèÂàÜÊàê‰∫Ü6ÁªÑÔºåÂ¶Ç‰∏ãÔºö
Ëøô6ÁªÑÂü∫Âõ†ÈõÜÁâπÊÄßÊòØÔºö
 Genes in Clusters 1 and 2 were continuously and monotonically downregulated and upregulated from the second to fourth weeks after orthotropic implantation, respectively.]]></description>
</item>
<item>
    <title>„Äêbioinfo„Äë-Q&amp;A-55</title>
    <link>https://uioqps.github.io/bioinfo-q-a-55/</link>
    <pubDate>Fri, 21 Feb 2020 22:02:52 &#43;0000</pubDate>
    <author>Milky</author>
    <guid>https://uioqps.github.io/bioinfo-q-a-55/</guid>
    <description><![CDATA[pan-cancer Ê≥õÁôåÁ†îÁ©∂‰πãÊã∑Ë¥ùÊï∞ÂèòÂºÇ ÂèëË°®‰∫é September 2013 Pan-cancer patterns of somatic copy number alteration
ÂØπÊã∑Ë¥ùÊï∞ÁöÑÂàÜÁ±ªÊï¥ÁêÜ We identified a total of 202,244 SCNAs, a median of 39 per cancer sample, comprising 6 categories:
 focal SCNAs that were shorter than the chromosome arm (median of 11 amplifications and 12 deletions per sample); arm-level SCNAs that were chromosome-arm length or longer (median of 3 amplifications and 5 deletions per sample); copy-neutral loss-of-heterozygosity (LOH) events in which one allele was deleted and the other was amplified coextensively (median of 1 per sample); whole-genome duplications (WGDs; in 37% of cancers).]]></description>
</item>
<item>
    <title>„Äêbioinfo„Äë-Q&amp;A-54</title>
    <link>https://uioqps.github.io/bioinfo-q-a-54/</link>
    <pubDate>Fri, 21 Feb 2020 22:02:48 &#43;0000</pubDate>
    <author>Milky</author>
    <guid>https://uioqps.github.io/bioinfo-q-a-54/</guid>
    <description><![CDATA[Êé¢Á¥¢FGFR3-TACC3Âü∫Âõ†ËûçÂêàÊú∫Âà∂ FGFR3-TACC3Âü∫Âõ†ËûçÂêàÊú∫Âà∂Êé¢Á©∂ A metabolic function of FGFR3-TACC3gene fusions in cancer, ÁæéÂõΩÂì•‰º¶ÊØî‰∫öÂ§ßÂ≠¶ÂåªÂ≠¶‰∏≠ÂøÉÔºàCUMCÔºâÁöÑÁ†îÁ©∂‰∫∫ÂëòÂèëÁé∞‰∏§‰∏™Áõ∏ÈÇªÂü∫Âõ†ÁöÑËûçÂêàËÉΩÂ§üÂØºËá¥Á∫øÁ≤í‰ΩìËøáÂ∫¶ËøêËΩ¨ÂíåÂ¢ûÂä†ÁªÜËÉûÁñØÁãÇÁîüÈïøÊâÄÈúÄÁöÑÁáÉÊñôÊï∞ÈáèÔºå‰ªéËÄåÂØºËá¥ÁôåÁóá‰∫ßÁîü„ÄÇ‰ªñ‰ª¨‰πüÂèëÁé∞Âú®‰∫∫ÁôåÁªÜËÉûÂíå‰∏ÄÁßçËÑëÁôåÁ±ªÂûãÁöÑÂ∞èÈº†Ê®°Âûã‰∏≠ÔºåÈù∂ÂêëËøô‰∏™Êñ∞Èâ¥ÂÆöÂá∫ÁöÑÁôåÁóáÈÄöË∑ØÁöÑËçØÁâ©ËÉΩÂ§üÈòªÊ≠¢ËÇøÁò§ÁîüÈïø„ÄÇ
ÂÖ®ÊñáÁöÑÈáçÁÇπÂ∫îËØ•ÊòØÂÆûÈ™åÊé¢Á¥¢ÂèäÈ™åËØÅFGFR3-TACC3Âü∫Âõ†ËûçÂêàÊú∫Âà∂„ÄÇ
FGFR3-TACC3Âü∫Âõ†ËûçÂêà‰∫ã‰ª∂ ‰ΩúËÄÖÂú®‰ª•ÂâçÁöÑGBMÁ†îÁ©∂Ôºà2012Âπ¥ÂèëË°®Âú®ScienceÊúüÂàä‰∏äÁöÑ‰∏ÄÈ°πÁ†îÁ©∂Ôºâ‰∏≠Â∞±ÂèëÁé∞‰∫ÜÁ∫¶Êúâ3%ÁöÑFGFR3-TACC3Âü∫Âõ†ËûçÂêàÁé∞Ë±°ÔºåËÄå‰∏îÂêåÊó∂ÊúüÂæàÂ§öÂÖ∂ÂÆÉÁôåÁóá‰πüÂèëÁé∞‰∫ÜÂêåÊ†∑ÁöÑËûçÂêà‰∫ã‰ª∂„ÄÇËôΩÁÑ∂FGFR3-TACC3Âü∫Âõ†ËûçÂêàË°®Áé∞Âá∫ÂéüÁôåÂü∫Âõ†ÁöÑÁâπÊÄßÔºå‰ºöÂΩ±ÂìçFGFRÊäëÂà∂ÂâÇÁöÑÊïàÊûúÔºå‰ΩÜÊòØÂÆÉÁöÑ‰∏ãÊ∏∏Ë∞ÉÊéßÊú∫Âà∂Á†îÁ©∂ÁöÑÂπ∂‰∏çÊ∏ÖÊ•ö„ÄÇ
 È¢òÂ§ñËØùÔºöÊúâË∂£ÁöÑÊòØÊàëÂàÜÊûê‰∫Ü‰∏Ä‰∏™Âè∞Êπæ‰∫∫ÁöÑOSCC cohortÁöÑËΩ¨ÂΩïÁªÑÊï∞ÊçÆÔºå‰πüÂèëÁé∞‰∫ÜËøô‰∏™FGFR3-TACC3Âü∫Âõ†ËûçÂêàÁé∞Ë±°„ÄÇ
 ËÆ∫ÊñáÂÖ±ÂêåÈÄö‰ø°‰ΩúËÄÖ„ÄÅCUMCÁôåÁóáÈÅó‰º†Â≠¶Á†îÁ©∂ÊâÄÁ•ûÁªèÁóÖÂ≠¶ÊïôÊéà„ÄÅÁóÖÁêÜÂ≠¶‰∏éÁªÜËÉûÁîüÁâ©Â≠¶ÊïôÊéàAntonio IavaroneÂçöÂ£´ËØ¥Ôºå‚Äú**ËøôÂèØËÉΩÊòØ‰∫∫Á±ªÁôåÁóá‰∏≠ÂîØ‰∏ÄÊúÄ‰∏∫Â∏∏ËßÅÁöÑÂü∫Âõ†ËûçÂêà„ÄÇ**Êàë‰ª¨ÊÉ≥Ë¶ÅÁ°ÆÂÆöFGFR3-TACC3ËûçÂêàÂ¶Ç‰ΩïËØ±ÂØºÂíåÁª¥ÊåÅÁôåÁóáÔºåËøôÊ†∑Êàë‰ª¨Â∞±ÂèØËÉΩÈâ¥ÂÆöÂá∫ËçØÁâ©Ê≤ªÁñóÁöÑÊñ∞Èù∂Ê†á„ÄÇ‚Äù
Á∫øÁ≤í‰ΩìÊ¥ªÊÄß ÈïøÊúü‰ª•Êù•Ôºå‰∫∫‰ª¨Â∑≤Âú®ÁôåÁóá‰∏≠ËßÇÂØüÂà∞Á∫øÁ≤í‰ΩìÂèòÂåñÔºå‰ΩÜÊòØ‰ªÖÂú®ËøëÊúüÊâçÂèëÁé∞Á∫øÁ≤í‰ΩìÊ¥ªÊÄßÂíåÁªÜËÉû‰ª£Ë∞¢‰∏éÊüê‰∫õÁôåÁóáÂ≠òÂú®ÂÖ≥ËÅî„ÄÇÁÑ∂ËÄåÔºåÂü∫Âõ†Á™ÅÂèòÊîπÂèòÁ∫øÁ≤í‰ΩìÊ¥ªÊÄßÂíå‰øÉËøõËÇøÁò§ÁîüÈïøÁöÑÊú∫Âà∂ÊòØÊú™Áü•ÁöÑ„ÄÇ
Âú®ÂΩìÂâçÁöÑËøôÈ°πÁ†îÁ©∂‰∏≠ÔºåËøô‰∫õÁ†îÁ©∂‰∫∫ÂëòÊØîËæÉ‰∫ÜÊê∫Â∏¶ÁùÄFGFR3-TACC3ÂíåÊú™Êê∫Â∏¶ÁùÄFGFR3-TACC3ÁöÑÁôåÁªÜËÉû‰∏≠ÁöÑ‰∏äÂçÉ‰∏™Âü∫Âõ†ÁöÑÊ¥ªÊÄß„ÄÇ‰ªñ‰ª¨ÂèëÁé∞ËøôÁßçËûçÂêàÊûÅÂ§ßÂú∞Â¢ûÂä†Á∫øÁ≤í‰ΩìÁöÑÊï∞ÈáèÂíåÂ¢ûÂä†ÂÆÉ‰ª¨ÁöÑÊ¥ªÊÄß„ÄÇÈâ¥‰∫éÁôåÁªÜËÉûÈúÄË¶ÅÂ§ßÈáèÁöÑËÉΩÈáèÊâçËÉΩÂø´ÈÄüÂú∞ÂàÜË£ÇÂíåÁîüÈïøÔºåÂΩìÁ∫øÁ≤í‰ΩìÁöÑÊ¥ªÊÄßÂ¢ûÂä†Êó∂ÔºåËøô‰∫õÁôåÁªÜËÉûÂ∞±ËÉΩÂ§üËåÅÂ£ÆÁîüÈïø„ÄÇ
ÈÄöËøáÈááÁî®Â§öÁßçÂÆûÈ™åÊäÄÊúØÔºåËøô‰∫õÁ†îÁ©∂‰∫∫ÂëòÁ°ÆÂÆöËøôÁßçÂü∫Âõ†ËûçÂêàÂêØÂä®‰∫Ü‰∏ÄÁ≥ªÂàóÂ¢ûÂº∫Á∫øÁ≤í‰ΩìÊ¥ªÊÄßÁöÑ‰∫ã‰ª∂„ÄÇ
 È¶ñÂÖàÔºåFGFR3-TACC3ÊøÄÊ¥ª‰∏ÄÁßçË¢´Áß∞‰ΩúPIN4ÁöÑËõãÁôΩ„ÄÇ‰∏ÄÊó¶ÈÅ≠ÂèóÊøÄÊ¥ªÔºåPIN4ËøÅÁßªÂà∞ËøáÊ∞ßÂåñÁâ©ÈÖ∂‰Ωì‰∏≠„ÄÇ ‰Ωú‰∏∫‰∏ÄÁßçÁªÜËÉûÂô®ÔºåËøáÊ∞ßÂåñÁâ©ÈÖ∂‰ΩìÂ∞ÜËÑÇËÇ™ÈôçËß£‰∏∫Â¢ûÂä†Á∫øÁ≤í‰ΩìÊ¥ªÊÄßÁöÑÁâ©Ë¥®„ÄÇÂèóÂà∞ÊøÄÊ¥ªÁöÑPIN4Ëß¶Âèë‰∫ßÁîüÁöÑËøáÊ∞ßÂåñÁâ©ÈÖ∂‰ΩìÊï∞ÈáèÂ¢ûÂä†‰∫Ü4ÔΩû5ÂÄçÔºå‰ªéËÄåÈáäÊîæÂ§ßÈáèÁöÑÊ∞ßÂåñÂâÇ„ÄÇ ÊúÄÂêéÔºåËøô‰∫õÊ∞ßÂåñÂâÇËØ±ÂØºPGC1Œ±‰∫ßÁîü„ÄÇ‰Ωú‰∏∫Á∫øÁ≤í‰Ωì‰ª£Ë∞¢ÁöÑ‰∏ÄÁßçÂÖ≥ÈîÆÁöÑË∞ÉÊéßÁâ©ÔºåPGC1Œ±Â¢ûÂä†Á∫øÁ≤í‰ΩìÁöÑÊ¥ªÊÄßÂíåËÉΩÈáè‰∫ßÁîü„ÄÇ  ËØ¥Êòé‰∫Ümitochondrial respirationÂèØ‰ª•‰Ωú‰∏∫ÊúâFGFR3-TACC3Âü∫Âõ†ËûçÂêàÂèëÁîüÁöÑÈÇ£ÈÉ®ÂàÜÁôåÁóáÊÇ£ËÄÖÁöÑÊ≤ªÁñóÈù∂ÁÇπ„ÄÇ
Ë°®ËææËäØÁâáÊï∞ÊçÆÂàÜÊûê ‰ΩúËÄÖÈÄöËøáÂÆûÈ™åÊâãÊÆµÊûÑÈÄ†‰∫ÜÂê´ÊúâFGFR3-TACC3ËûçÂêàÂü∫Âõ†ÁöÑastrocyteÁªÜËÉûÁ≥ªÔºåÁúãÂÆÉ‰ª¨ÁªèËøá‰∫ÜFGFR tyrosine kinase (TK, PD173074) or vehicleÂ§ÑÁêÜÂêéÁöÑÂü∫Âõ†Ë°®ËææÂå∫Âà´ÔºåËøòÊúâ‰∏Ä‰∏™ÊØîËæÉÁâπÊÆäÁöÑÁªÑÊòØ kinase-dead F3‚ÄìT3 (F3‚ÄìT3(K508M)) ÔºåËøô‰∏™ËôΩÁÑ∂FGFR3-TACC3‰πüËûçÂêàÔºå‰ΩÜÊòØÊúâ‰∏Ä‰∏™Á™ÅÂèò‰ΩçÁÇπÔºåÂØºËá¥ÂÖ∂Ë°®ËææÁöÑ‰∫ßÁâ©ÊòØ‰∏çÂÖ∑Â§áÊøÄÈÖ∂Ê¥ªÊÄßÁöÑ„ÄÇ
ÂàÜÁªÑÂ¶Ç‰∏ãÔºö
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  F3T3_1 FGFR3-TACC3 treated with vehicle F3T3_2 FGFR3-TACC3 treated with vehicle F3T3_3 FGFR3-TACC3 treated with vehicle F3T3_4 FGFR3-TACC3 treated with vehicle F3T3_5 FGFR3-TACC3 treated with vehicle F3T3_KD_1 Empty vector treated with vehicle F3T3_KD_2 Empty vector treated with vehicle F3T3_KD_3 Empty vector treated with vehicle F3T3_PD_1 FGFR3-TACC3 treated with the FGFR inhibitor PD173074 for 12h F3T3_PD_2 FGFR3-TACC3 treated with the FGFR inhibitor PD173074 for 12h F3T3_PD_3 FGFR3-TACC3 treated with the FGFR inhibitor PD173074 for 12h F3T3_PD_4 FGFR3-TACC3 treated with the FGFR inhibitor PD173074 for 12h F3T3_PD_5 FGFR3-TACC3 treated with the FGFR inhibitor PD173074 for 12h VECTOR_1 FGFR3-TACC3-K508M treated with vehicle VECTOR_2 FGFR3-TACC3-K508M treated with vehicle VECTOR_3 FGFR3-TACC3-K508M treated with vehicle Ë°®ËææËäØÁâáÊï∞ÊçÆÂèØ‰ª•‰∏ãËΩΩÔºåE-MTAB-6037 Ôºå Áî®ÁöÑÊòØ Illumina HumanHT-12 V4.]]></description>
</item>
<item>
    <title>„Äêbioinfo„Äë-Q&amp;A-53</title>
    <link>https://uioqps.github.io/bioinfo-q-a-53/</link>
    <pubDate>Fri, 21 Feb 2020 22:02:45 &#43;0000</pubDate>
    <author>Milky</author>
    <guid>https://uioqps.github.io/bioinfo-q-a-53/</guid>
    <description><![CDATA[Â§öÈù∂ÁÇπËá™‰ΩìÂÖçÁñ´ÁªÜËÉûÊäÄÊúØ ËøáÁªßÊÄßTÁªÜËÉûÊ≤ªÁñó(adoptive T-cell therapy,ACT) ÊñáÁ´†ÊòØ Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer ÂèëË°®‰∫é Nature Medicine (2018) ÈáçÁÇπÂú®ÂÆûÈ™åËÆæËÆ°ÁéØËäÇÔºå‰ΩÜÊòØÁé∞Âú®ÁöÑÂ§ßÊñáÁ´†ÊàñÂ§öÊàñÂ∞ëÈÉΩÂºïÂÖ•Â§öÁªÑÂ≠¶Êï∞ÊçÆÔºåÊú¨Êñá‰πü‰∏ç‰æãÂ§ñÔºåÂÆûÈ™åÁ∫≥ÂÖ•ÁöÑÂîØ‰∏Ä‰∏Ä‰∏™ÁóÖ‰∫∫Êó¢ÂÅö‰∫ÜÂÖ®Â§ñÊòæÂ≠êÂèàÂÅö‰∫ÜËΩ¨ÂΩïÁªÑÊµãÂ∫èÔºåËøòÊúâÂçïÁªÜËÉûÊµãÂ∫è„ÄÇ‰∏çËøáÊï∞ÊçÆÂÖ¨ÂºÄÁöÑÊòØ PRJNA342632 for exome data and PRJNA243084 for RNA-seq data
ËÉåÊôØÁü•ËØÜ ËÇøÁò§ÂÖçÁñ´ÁñóÊ≥ï ËøëÂπ¥Êù•ÔºåËÇøÁò§ÂÖçÁñ´ÁñóÊ≥ïÂ∑≤Êàê‰∏∫ÁªßÊâãÊúØ„ÄÅÊîæÁñóÂíåÂåñÁñó‰πãÂêéÁöÑÁ¨¨ÂõõÁßçËÇøÁò§Ê≤ªÁñóÊâãÊÆµ„ÄÇ
ËÇøÁò§ÂÖçÁñ´Ê≤ªÁñóÔºå‰∏ªË¶ÅÂåÖÊã¨
1 2 3 4 5  ÂÖçÁñ´Áñ´Ëãó ÂÖçÁñ´Ê£ÄÊü•ÁÇπÊäëÂà∂ÂâÇÊ≤ªÁñó ËøáÁªßÊÄßÂÖçÁñ´ÁªÜËÉûÊ≤ªÁñó ÁªÜËÉûÂõ†Â≠êÊ≤ªÁñó ÂÖ∂‰∏≠‰ª•CTLA4„ÄÅPD1/PDL1ÊäëÂà∂ÂâÇ‰∏∫‰ª£Ë°®ÁöÑÂÖçÁñ´Ê£ÄÊü•ÁÇπÊäëÂà∂ÂâÇÔºå‰ª•ÂÖ∂ÊòæËëóÁöÑ‰∏¥Â∫äÁñóÊïàËÄåÂ§áÂèóÁû©ÁõÆ„ÄÇ   ËÄåÊú¨ÊñáÁöÑÁ†îÁ©∂Â±û‰∫éËÇøÁò§ÂÖçÁñ´Ê≤ªÁñóÁöÑËøáÁªßÊÄßTÁªÜËÉûÁñóÊ≥ïÔºàACTÔºâÈ¢ÜÂüüÔºå‰πãÂâç‰ª•CART‰∏∫‰∏ªÔºåÊúÄËøëÂá∫Áé∞‰∫ÜÂè¶Â§ñ‰∏ÄÁßçÁñóÊ≥ï‚Äî‚ÄîTILÔºàTumor Infiltrating T cellÔºåËÇøÁò§Êµ∏Ê∂¶Ê∑ãÂ∑¥ÁªÜËÉûÔºâÔºåË°®Áé∞‰πüÂçÅÂàÜÊÉäËâ≥ÔºåRosenburgÂçöÂ£´ÂèäÂÖ∂Âõ¢ÈòüÂ∞±ÊòØËøô‰∏ÄÈ¢ÜÂüüÁöÑ‰ª£Ë°®„ÄÇ
ËÇøÁò§Êµ∏Ê∂¶Ê∑ãÂ∑¥ÁªÜËÉû(TILs) ËÇøÁò§Êµ∏Ê∂¶ÊÄßÊ∑ãÂ∑¥ÁªÜËÉûÔºàtumor infiltrating lymphocyte, TILÔºâÊåáÁöÑÊòØ‰ªéËÇøÁò§ÁªÑÁªá‰∏≠ÂàÜÁ¶ªÂá∫ÁöÑÊµ∏Ê∂¶Ê∑ãÂ∑¥ÁªÜËÉû„ÄÇ
1986Âπ¥ÔºåRosenbergÁ†îÁ©∂ÁªÑÈ¶ñÂÖàÊä•ÈÅì‰∫ÜTILÁªÜËÉû„ÄÇTILÁªÜËÉûË°®ÂûãÂÖ∑ÊúâÂºÇË¥®ÊÄß„ÄÇ‰∏ÄËà¨Êù•ËØ¥ÔºåÂú®TIL‰∏≠ÔºåÁªùÂ§ßÂ§öÊï∞ÁªÜËÉûÊòØCD3Èò≥ÊÄßÁöÑ„ÄÇÂú®‰∏çÂêåËÇøÁò§Êù•Ê∫êÁöÑTILÁªÜËÉû‰∏≠ÔºåCD4+ TÁªÜËÉû„ÄÅCD8+ TÁªÜËÉûÁöÑÊØî‰æãÊúâÂ∑ÆÂºÇÔºå‰ΩÜÂ§ßÂ§öÊï∞ÊÉÖÂÜµ‰∏ã‰ª•CD8+TÁªÜËÉû‰∏∫‰∏ª„ÄÇ
‰∏çÂêåÊÇ£ËÄÖ‰∏çÂêåËÇøÁò§Á±ªÂûãÂØπÂÖçÁñ´ÁñóÊ≥ïÁöÑÂèçÂ∫î‰∏çÂèØÈ¢ÑÊµãÔºåÊòØÂõ†‰∏∫ÂÖçÁñ´ÊàêÂàÜÁöÑÂºÇË¥®ÊÄß‰ª•ÂèäËÇøÁò§Êµ∏Ê∂¶Ê∑ãÂ∑¥ÁªÜËÉûÔºàTILsÔºâÂú®Âçï‰∏™ËÇøÁò§ÂÜÖÂíåÊÇ£ËÄÖ‰πãÈó¥ÁöÑÂ§öÊ†∑ÂåñË°®Âûã„ÄÇ
Âπ∂‰∏çÊòØÊâÄÊúâÁöÑËÇøÁò§Êµ∏Ê∂¶TÁªÜËÉûÈÉΩÊòØÈíàÂØπËÇøÁò§ÊäóÂéüÁöÑÔºåÂπ∂‰∏îÂèëÁé∞Ê£ÄÊµãCD39ÁöÑË°®ËææÂèØ‰ª•ÁÆÄÂçïÁöÑÈáèÂåñÊàñÂàÜÁ¶ªBystander Âç≥‚ÄúÊóÅËßÇËÄÖ‚ÄùTÁªÜËÉû„ÄÇ
ÊäÄÊúØÂéÜÂè≤ Êó©Âú®2014Âπ¥ÁöÑÊó∂ÂÄôRosenburgÂçöÂ£´ÁöÑÂõ¢ÈòüÂ∞±Â∞ÜÂÖ∂‰∏ÄÈÉ®ÂàÜÁ†îÁ©∂ÁªìÊûúÂèëË°®Âú®ScienceÊúüÂàäÔºàTran E et al, Science 2014Ôºâ‰∏äÔºåÂΩìÊó∂‰ªñ‰ª¨ÁöÑÂÅöÊ≥ïÊòØÔºöÊää‰∏ÄÂêçÊôöÊúüËÉÜÁÆ°ÁôåÂ•≥ÊÇ£ËÄÖÁöÑËÇ∫ËΩ¨ÁßªËÇøÁò§ÁóÖÁÅ∂ÊãøÊù•ÂÅöÂÖ®Âü∫Â§ñÊòæÂ≠êÊµãÂ∫èÔºåÊâæÂà∞‰∫Ü26‰∏™ÈùûÂêå‰πâÁ™ÅÂèòÔºåÂπ∂‰∏∫ÊØè‰∏Ä‰∏™Á™ÅÂèòÊûÑÂª∫‰∫Ü‰∏ÄÊÆµÁü≠Âü∫Âõ†ÔºåÂ∞ÜËøô‰∫õÁü≠Âü∫Âõ†Âá†‰∏™‰∏ÄÁªÑÂú∞‰∏≤ËÅîÊàêÁü≠Âü∫Âõ†‰∏≤ÔºàTandem Minigene, TMGÔºâÔºåÁÑ∂ÂêéÂ∞ÜËøô‰∫õÁü≠Âü∫Âõ†‰∏≤ËΩ¨ÂÖ•ÊäóÂéüÈÄíÂëàÁªÜËÉûÔºàÊåáÊ†ëÁ™ÅÁä∂ÁªÜËÉûDCÔºâÂπ∂‰∏éËÇøÁò§Êµ∏Ê∂¶Ê∑ãÂ∑¥ÁªÜËÉûÔºàTILÔºâÂÖ±ÂêåÂüπÂÖªÔºå‰ª•Êü•ÁúãÊÇ£ËÄÖÁöÑTIL‰∏≠ÊòØÂê¶Â≠òÂú®ÂèØ‰ª•ÁâπÂºÇÊÄßËØÜÂà´ËÇøÁò§Á™ÅÂèòÁöÑTÁªÜËÉû„ÄÇ‰∏çÂá∫ÊâÄÊñôÔºåËøô‰ΩçÊÇ£ËÄÖÁöÑTILÂèØ‰ª•ËØÜÂà´ËÇøÁò§ÁöÑ‰∏Ä‰∏™Á™ÅÂèò„ÄÇÁ†îÁ©∂ËÄÖÂ∞ÜËøô‰∏™ÊúâËØÜÂà´ÂäüËÉΩÁöÑTÁªÜËÉû‰ΩìÂ§ñÂ§ßÈáèÊâ©Â¢ûÂêéÂÜçÂõûËæìÁªôÊÇ£ËÄÖÔºåÊÇ£ËÄÖËÇùÈÉ®ÁöÑËΩ¨ÁßªÁÅ∂ÈïøÊúüÁ®≥ÂÆöÁä∂ÊÄÅËææ1Âπ¥‰ª•‰∏ä„ÄÇRosenburgÂçöÂ£´ÁöÑÂõ¢ÈòüÈÄöËøáËøô‰∏™Á†îÁ©∂ÔºåËØÅÊòé‰∫ÜÊôöÊúüÁôåÁóáÊÇ£ËÄÖÁöÑËÇøÁò§ÁªÑÁªá‰∏≠Á°ÆÂÆûÊòØÂ≠òÂú®ÂèØ‰ª•ÂØπÊäóËÇøÁò§Á™ÅÂèòÁöÑÊ∑ãÂ∑¥ÁªÜËÉûÁöÑ„ÄÅÂç≥‰æøÊòØÂú®ÊôöÊúüËÉÜÁÆ°ÁôåËøôÊ†∑Âá∂Èô©ÂèàÈöæÊ≤ªÁöÑÁò§Áßç„ÄÇ]]></description>
</item>
<item>
    <title>„Äêbioinfo„Äë-Q&amp;A-52</title>
    <link>https://uioqps.github.io/bioinfo-q-a-52/</link>
    <pubDate>Fri, 21 Feb 2020 22:02:41 &#43;0000</pubDate>
    <author>Milky</author>
    <guid>https://uioqps.github.io/bioinfo-q-a-52/</guid>
    <description><![CDATA[PDAC-organoids ËÉ∞ËÖ∫ÁôåÁöÑÁ±ªÂô®ÂÆòÂèØ‰ª•ËæÖ‰ΩêÊ≤ªÁñóÂÜ≥Á≠ñ PDACËÉåÊôØÁü•ËØÜ ËÉ∞ËÖ∫ÁôåÁîüÈïøÂø´ËÄå‰∏îËΩ¨ÁßªÁéáÈ´òÔºåÊòØ‰∏ÄÁßçÈùûÂ∏∏Ëá¥ÂëΩÁöÑÊÅ∂ÊÄßÁñæÁóÖ„ÄÇ2016Âπ¥ÁæéÂõΩÁôåÁóáÂçè‰ºöÁöÑÊï∞ÊçÆÊòæÁ§∫ÔºåËÉ∞ËÖ∫ÁôåÊÇ£ËÄÖÁöÑ5Âπ¥ÁîüÂ≠òÁéáÂú®7-8%‰πãÈó¥„ÄÇËôΩÁÑ∂ÊâãÊúØÂèØ‰ª•Ê†πÊ≤ªËøôÁßçÁñæÁóÖÔºå‰ΩÜËÉ∞ËÖ∫ÁôåÂú®Á°ÆËØäÊó∂Âè™Êúâ10‚Äì20%ÊòØÂèØÂàáÈô§ÁöÑÔºåÂÖ∂ÂÆÉÊÇ£ËÄÖÂè™ËÉΩÊé•ÂèóÂåñÁñó„ÄÇ
2Êúà8Êó•Âú®Nature Communications‰∏äÂèëË°®ÁöÑGWASÁ†îÁ©∂Á∫≥ÂÖ•‰∫Ü21,536‰∫∫ÔºåÂèëÁé∞‰Ωç‰∫é‰∫∫Á±ªÊüìËâ≤‰Ωì1Ôºà‰ΩçÁΩÆ1p36.33Ôºâ„ÄÅ7Ôºà‰ΩçÁΩÆ7p12Ôºâ„ÄÅ8Ôºà‰ΩçÁΩÆ8q21.11Ôºâ„ÄÅ17Ôºà‰ΩçÁΩÆ17q12ÔºâÂíå18Ôºà‰ΩçÁΩÆ18q21.32Ôºâ‰∏äÁöÑÊñ∞Èâ¥ÂÆöÁöÑÈÅó‰º†ÂèòÂºÇÂèØÂ¢ûÂä†ËÉ∞ËÖ∫ÁôåÈ£éÈô©„ÄÇËøô‰∫õÂü∫Âõ†ÁªÑ‰∏≠ÊØè‰∏™Êã∑Ë¥ùÁöÑÂ≠òÂú®ÈÉΩ‰ºöÂ¢ûÂä†ËÉ∞ËÖ∫ÁôåÈ£éÈô©15ÔºÖ-25ÔºÖ„ÄÇ
ÂÖ≥‰∫éËÉ∞ËÖ∫ÁôåÂèëÁîüÁöÑÁºòËµ∑ÂÅáËØ¥ÁõÆÂâç‰∏ªË¶ÅÈõÜ‰∏≠Âú®‰∏§‰∏™Â≠¶ËØ¥Ôºå‰∏Ä‰∏™ÊòØÊúÄÊó©Áî±ËÇøÁò§ÈÅó‰º†Â≠¶‰º†Â•á‰∫∫Áâ©Alfred G KnudsonÊèêÂá∫ÁöÑËÇøÁò§ÁöÑ‚Äú‰∫åÊ¨°ÊâìÂáªÂ≠¶ËØ¥‚ÄùÔºåÂÖ∂ÂêéÁî±ËØ∏Â§öËÉ∞ËÖ∫ÁôåÁ†îÁ©∂È¢ÜÂüüÁöÑÁßëÂ≠¶ÂÆ∂ÂÆåÂñÑÂπ∂Á°ÆÂÆöÊèêÂá∫ÁöÑ‚ÄúKras-CDKN2A-P53-SMAD4‚ÄùÊàêÊ¨°Â∫èÊîπÂèòÂíåÈÄêÊ≠•ÁßØÁ¥ØÁöÑÊèèËø∞ËÉ∞ËÖ∫ËÇøÁò§Áî±PanINsÂèëÂ±ïËá≥PDACÁöÑÂ≠¶ËØ¥‰ΩìÁ≥ª„ÄÇËá™Ê≠§ÔºåÂè§ËÄÅÁöÑÂü∫‰∫éÁóÖÁêÜÂΩ¢ÊÄÅÁöÑÂ≠¶Áßë‰ΩìÁ≥ª‰∏éÊñ∞ÂûãÁöÑÂü∫‰∫éÂü∫Âõ†ÂàÜÂ≠êÁîüÁâ©ÂàÜÂûãÁöÑÂ≠¶Áßë‰ΩìÁ≥ªÂèòÂæó‰∏çÂÜçÂêÑËá™Â≠§Á´ãÔºöËøë20Âπ¥Èó¥ÁöÑÁ≥ªÂàóÁ†îÁ©∂Âú®ËÉ∞ËÖ∫Áôå‰∏≠ÊØîËæÉÊúâ‰ª£Ë°®ÊÄßÂú∞Âº∫Ë∞É‰∫ÜËÉ∞ËÖ∫ÁôåÁóÖÁêÜÂΩ¢ÊÄÅÊîπÂèòÂíåÂàÜÂ≠êÁîüÁâ©Â≠¶ÊîπÂèòÁöÑÂπ≥Ë°åÁõ∏ÂÖ≥ÊÄß„ÄÇËÄå2017Âπ¥ÁöÑ‰∏ÄÈ°πÊù•Ëá™dana farberÂíåÂìàÂºóÂåªÂ≠¶Èô¢ÁöÑÊúÄÊñ∞Á†îÁ©∂Êõ¥ÊòØÂú®356‰æãËÉ∞ËÖ∫ÁôåÊ†∑Êú¨‰∏≠ËæÉ‰∏∫ÂÖ®Èù¢ÂíåÂÆåÊï¥Âú∞ÁöÑÊé¢Á¥¢Âõõ‰∏™ÂÖ≥ÈîÆÈ©±Âä®Âü∫Âõ†ÊîπÂèò‰∏éËÉ∞ËÖ∫ÁôåÈ¢ÑÂêéÁöÑÁõ∏ÂÖ≥ÊÄßÔºàÂõõÂ§ßÈ©±Âä®Âü∫Âõ†‰∏≠ÔºåKRASÂíåCDKN2A‰∏é‰∏¥Â∫äÈ¢ÑÂêéÁ¥ßÂØÜÁõ∏ÂÖ≥Ôºõ‰∏éÊ≠§ÂêåÊó∂ÔºåÈ©±Âä®Âü∫Âõ†ÁöÑÁ™ÅÂèò‰∏™Êï∞Ë∂äÂ§öÔºåÈ¢ÑÂêéË∂äÂ∑ÆÔºâ
TCGAÊï∞ÊçÆÂàÜÊûêPDACÂàÜÊàê‰∏§‰∏™Â§ßÁ±ªÔºö
 The Basal-like, Squamous or Quasi-mesenchymal, subtype identifies PDAC patients with poor prognosis and is characterized by basal markers such as cytokeratins. The Classical or Pancreatic Progenitor subtype is characterized by differentiated ductal markers and identifies patients with a better prognosis.  ÂÆûÈ™åËÆæËÆ° Êú¨Á†îÁ©∂ÊòØ‰ªéPDACÁóÖ‰∫∫ÁöÑËÇøÁò§ÈÉ®ÂàÜÂèñÊ†∑ÂÅö3DÂüπÂÖªÔºö
ÊÄªÂÖ±ÊòØ138‰∏™ÁóÖ‰∫∫ÔºåÈáåÈù¢Âèñ‰∫Ü 159‰∏™Ê†∑ÂìÅÔºåÂåÖÊã¨ primary tumors (hT) metastases (hM)
 78 ‰∏™Ê†∑Êú¨ÊòØspecimens were isolated from surgical resections 60 ‰∏™Ê†∑Êú¨ÊòØfine needle biopsies of primary or metastatic lesions (hF) 20‰∏™Ê†∑Êú¨ÊòØ metastatic disease following rapid autopsies 1‰∏™Ê†∑Êú¨ÊòØa video-assisted thoracoscopic surgical (VATS) resection of a lung metastasis.]]></description>
</item>
</channel>
</rss>
